Tag Archives: Drugs and Pharmaceuticals

Zeteo Biomedical Expands into Pulmonary Drug Delivery with AriesMR Active Dry Powder Inhaler

New ZTECH-P™ pulmonary platform provides active, propellant-free powder aerosolization without reliance on patient inspiratory effort and supports single- and dual-API combination products

AUSTIN, Texas, Sept. 15, 2026 (SEND2PRESS NEWSWIRE) — Zeteo Biomedical LLC today announced the expansion of its ZTECH-P™ powder drug-delivery platform into pulmonary delivery with the introduction of AriesMR™, a reloadable active dry powder inhaler designed for controlled pulmonary administration of pharmaceutical powders without reliance on patient-generated inspiratory energy for powder aerosolization or the use of CFC/HFA propellants.

Image caption: AriesMR™ Active Dry Powder Inhaler.

Unlike conventional passive dry powder inhalers that depend substantially on a patient’s inspiratory effort to disperse and aerosolize a formulation, AriesMR uses an integrated mechanical energy source to actively aerosolize and deliver the powder. The orientation-independent platform provides configurable dose and aerosolization parameters that can be optimized with formulation and particle characteristics for pulmonary delivery.

“AriesMR extends technologies we have developed and refined for nasal powder delivery into a pulmonary platform designed around many of the same challenges our pharmaceutical partners face—dose control, formulation protection, combination-product development and scalable manufacturing,” said Timothy Sullivan, Founder and Chief Executive Officer of Zeteo Biomedical.

“Importantly, the technology provides active powder aerosolization without requiring either HFA propellants or the patient’s inspiratory effort as the primary energy source for powder dispersion.”

The platform provides pharmaceutical developers with another approach to pulmonary combination-product development at a time when the industry is evaluating new inhalation technologies, including propellant-free alternatives to conventional pressurized inhaler platforms.

AriesMR incorporates replaceable unit-dose powder cartridges in a compact, mechanically actuated device, with on-board storage for up to six cartridges and a removable and replaceable mouthpiece. The device requires no battery power and is designed to operate independently of device orientation.

The platform can support single-API and dual-API configurations, including architectures in which separate powder formulations are maintained within the primary packaging until the point of delivery. This capability may enable combination-product strategies where formulation compatibility, stability or other development considerations make conventional co-formulation difficult.

AriesMR is being developed as part of Zeteo’s integrated combination-product development platform, bringing together delivery-device engineering, formulation and particle optimization, unit-dose primary packaging, product characterization and manufacturing technology. The platform is designed to support programs from early feasibility and preclinical development through clinical translation and commercial scale-up.

The expansion into pulmonary delivery builds on Zeteo’s existing ZTECH-P™ and ZTECH-L™ platforms supporting nasal, nose-to-brain, ophthalmic, sublingual and other non-invasive routes of administration.

Sullivan will participate in the IPAC-RS 2026 Nasal Innovation Forum, September 16–17 in Jersey City, New Jersey, where Zeteo will present work involving its intranasal powder delivery technology and meet with pharmaceutical and drug-delivery developers.

“Many of the formulation, device, primary-container and manufacturing challenges encountered in nasal powder development have direct parallels in pulmonary combination-product development,” Sullivan added. “The Forum provides an opportunity to discuss how those capabilities can be applied across both routes and to explore pulmonary programs where an active, propellant-free powder delivery approach may offer advantages.”

Learn more: https://zeteobiomed.com/pulmonary-drug-delivery/

ABOUT ZETEO BIOMEDICAL

Zeteo Biomedical LLC is a Cedar Park, Texas-based drug delivery technology and combination-product development company. Zeteo develops configurable delivery platforms for powder and liquid formulations across nasal, pulmonary, ophthalmic, sublingual and other non-invasive routes of administration. The company’s capabilities integrate delivery-device engineering, primary packaging, formulation and product development, in vitro characterization, manufacturing technology and commercialization support. For more information, visit Zeteo Biomedical to learn more about the AriesMR™ active dry powder inhaler: https://zeteobiomed.com/

Media Contact: Cathy Diehl, zeteo@zeteobiomed.com

MULTIMEDIA

Image link for media: https://www.Send2Press.com/300dpi/26-0915-s2p-ariesmr-300dpi.webp

Image caption: AriesMR™ Active Dry Powder Inhaler

LOGO: https://zeteobiomed.com/wp-content/uploads/2026/09/ZeteoLogo-transparent.png

NEWS SOURCE: Zeteo Biomedical LLC

This press release was issued on behalf of the news source (Zeteo Biomedical LLC), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/zeteo-biomedical-expands-into-pulmonary-drug-delivery-with-ariesmr-active-dry-powder-inhaler/

Florida Attorney General Uthmeier Becomes First in Nation to Subpoena CVS’s Secret Contracts with Drug Manufacturers, Distributors, and Pharmacies

Landmark Action Aims to Expose Opaque PBM Practices Driving Up Drug Costs and Threatening Independent Pharmacy Access

TALLAHASSEE, Fla., June 25, 2026 (SEND2PRESS NEWSWIRE) — Small Business Pharmacies Aligned for Reform (SPAR) today praised Florida Attorney General James Uthmeier for becoming the first attorney general in the United States to subpoena CVS’s confidential contracts with drug manufacturers, wholesale distributors, and both chain and independent retail pharmacies. The subpoenas represent a historic step toward exposing the secretive pricing and contracting practices of pharmacy benefit managers (PBMs) that patient advocates and independent pharmacists say have driven up prescription drug costs and jeopardized patients’ access to community pharmacy care.

Image caption: Small business Pharmacies Aligned for Reform (SPAR) is a group of Floridian neighborhood pharmacists and other advocates.

“We appreciate Attorney General Uthmeier for standing up to CVS and the vertically integrated PBMs on behalf of Floridians seeking answers to the continuing problems of ever-increasing price and shrinking patient accessibility to prescription medication,” said Dawn Butterfield, SPAR president. “Floridians are entitled to know and understand how PBM contract terms may affect their access to care and the price they pay at the pharmacy counter.”

“The subpoenas will compel CVS to produce contracts that have never been subject to public scrutiny, including agreements governing drug pricing with manufacturers, wholesaler purchase terms, and the reimbursement and network participation conditions imposed on retail pharmacies,” said Barney Bishop, SPAR’s CEO. “Transparency into these agreements will allow investigators to assess whether CVS’s contracting practices comply with state consumer protection and antitrust law, and whether patients are being harmed by the systemic elimination of independent pharmacy competition.”

“SPAR urges state attorneys general across the country to follow Florida’s lead and examine whether PBM contracting practices in their states are harming patients and independent pharmacies,” Mr. Bishop said.

ABOUT SPAR

Small business Pharmacies Aligned for Reform (SPAR) is a group of Floridian neighborhood pharmacists and other advocates focused stopping anti-competitive practices that PBMs use to short circuit the free market while placing additional burdens on patients and pharmacists. SPAR is committed to championing legislation that promotes neighborhood pharmacies’ ability to continue providing medications and care to the local patients and communities they serve. Learn more: https://www.sparfl.org/

REF: https://www.myfloridalegal.com/newsrelease/attorney-general-james-uthmeier-issues-subpoena-cvs-health-corporation-and-caremark

NEWS SOURCE: Florida Small Business Pharmacies Aligned for Reform (SPAR)

This press release was issued on behalf of the news source (Florida Small Business Pharmacies Aligned for Reform (SPAR)), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/florida-attorney-general-uthmeier-becomes-first-in-nation-to-subpoena-cvss-secret-contracts-with-drug-manufacturers-distributors-and-pharmacies/

HLA Protein Technologies Debuts sHLA-G Monomer and Tetramer Portfolio for High-Fidelity Checkpoint Biology, Target Validation, and Assay Development

OKLAHOMA CITY, Okla., Nov. 19, 2025 (SEND2PRESS NEWSWIRE) — HLA Protein Technologies, Inc. (formerly Pure Protein, LLC) today announced the commercial launch of its new soluble HLA-G (sHLA-G) product portfolio, marking an expansion of its next-generation HLA research tools.

Image caption: HLA Protein Technologies, Inc.

HLA-G PORTFOLIO HIGHLIGHTS

The Company’s broad new sHLA-G platform includes biotinylated monomers, fluorophore-labeled tetramers, and peptide-loaded complexes, produced using a proprietary mammalian expression system to ensure authentic folding, natural glycosylation, and physiologically relevant epitope presentation.

These reagents enable high-throughput screening, antibody validation, and translational research applications such as:

Drug discovery and immune checkpoint studies
Diagnostic assay development (ELISA, BLI, SPR)
Transplantation and autoimmunity research

HLA-G BIOLOGY AND RESEARCH IMPACT

HLA-G is a non-classical MHC Class I molecule recognized as a key immune checkpoint regulator. Its unique tolerogenic properties and restricted polymorphism make it critical for studies in immune tolerance, transplantation, oncology, autoimmunity, and infectious disease. Soluble isoforms of HLA-G exert powerful immunosuppressive effects, influencing NK cells, T cells, B cells, and dendritic cells – critical pathways for therapeutic development.

DEDICATED FOCUS ON HLA PROVIDES VALUE TO RESEARCHERS

Accelerated R&D: Ready-to-use, biologically accurate HLA reagents can accelerate project timelines.
World-Class Data Quality: Native-like sHLA-G molecules yield more predictive and reproducible results than non-soluble HLA.
Translational Confidence: sHLA closely reflects human biology, bridging the gap between bench research and clinical application.
Regulatory Readiness: Standardized, validated products support compliance and documentation for therapeutic development.

“Our sHLA-G portfolio marks a breakthrough for advancing next-generation immunotherapies, enabling researchers to decode and harness HLA-G–mediated immune regulation in cancer and transplantation.,” said Dr. Rico Buchli, Chief Scientist at HLA Protein Technologies. “By combining biological fidelity with scalable production, we’re providing tools that accelerate discovery and clinical translation.”

AVAILABILITY

The sHLA-G product line is now available for order at https://www.hlaprotein.com/products/hla-class-i/hla-g.

Custom projects and collaborations are supported through dedicated technical and licensing teams.

ABOUT HLA PROTEIN TECHNOLOGIES, INC.

HLA Protein Technologies, Inc., based in Oklahoma City, Oklahoma, specializes in high-purity HLA proteins, engineered cell lines and custom assay development.

With a focus on immunology and oncology, the company provides HLA-based reagents and services that enable discovery, lead validation and translational research. HLA Protein Technologies serves leading pharma, diagnostic and research customers in more than 20 countries.

Public and media queries: https://www.hlaprotein.com/contact-us

MULTIMEDIA:

Logo link for media: https://www.Send2Press.com/300dpi/25-0930-s2p-hlaprot-300dpi.webp

NEWS SOURCE: HLA Protein Technologies Inc.

This press release was issued on behalf of the news source (HLA Protein Technologies Inc.), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/hla-protein-technologies-debuts-shla-g-monomer-and-tetramer-portfolio-for-high-fidelity-checkpoint-biology-target-validation-and-assay-development/

Zeteo Biomedical Secures Global Patents for Nasal and Ophthalmic Drug Delivery Device Innovations

CEDAR PARK, Texas, June 11, 2025 (SEND2PRESS NEWSWIRE) — Zeteo Biomedical, a privately held biomedical device company, today announced the issuance of new patents in the United States and European Union for its advanced drug delivery technologies. The patents, titled “Cartridge Devices for Administration of a Medicament” (U.S. Patent No. 12329949) and “Hand-Operated Devices for Administration of a Medicament” (EU Patent No. 3946526), further strengthen Zeteo’s ZTech™ delivery platform portfolio for the administration of drugs and biologics via nasal, ophthalmic, and sublingual routes.

Image caption: Zeteo Biomedical.

These patented innovations advance Zeteo’s ZTech-L™ and ZTech-P™ delivery systems, which include both single-use disposable and multi-dose, cartridge-reloadable handheld devices. The platforms support the administration of therapeutics in both liquid and dry powder formulations, including vaccines, biologics, and specialty drugs. Nasal delivery, in particular, is emerging as a highly effective, non-invasive alternative for treating conditions such as pain, emesis, seizures, neurodegenerative and autoimmune disorders, infectious diseases, and bioterror threats.

“We are seeing increasing global demand for metered-dose nasal, ophthalmic, and sublingual delivery devices that are compact, intuitive, and suitable for self-administration,” said Timothy Sullivan, CEO of Zeteo Biomedical. “A unique feature that sets our device technology apart is its ability to function reliably in any physical orientation, making it ideal for medication delivery in both terrestrial and space-based microgravity environments. This capability opens exciting new frontiers for Zeteo including applications in space-based healthcare.”

Zeteo’s integrated delivery platforms and technical services streamline the development and commercial-scale production of patient-centric drug/device combination products for pharmaceutical and biotech partners. This focus on patient-friendly design improves treatment adherence and medical outcomes, while enhancing product differentiation and brand value for manufacturers.

Zeteo’s platform technologies are designed to meet the evolving demands of global and interstellar healthcare markets, delivering precision, performance, and portability for the next-generation of therapeutic drug/device combination products.

About Zeteo Biomedical LLC

Zeteo Biomedical is a Texas-based medical device company focused on the development and commercialization of advanced drug and biologic delivery systems. The company specializes in intranasal, ophthalmic, and sublingual delivery technologies designed to improve patient outcomes through precision dosing, portability, and ease of use. Zeteo’s proprietary platforms are supported by an extensive patent portfolio and a range of product development services tailored to accelerate time to market for pharmaceutical and biotech clients worldwide.

To learn more, visit https://zeteobiomed.com/.

MEDIA CONTACT:
Cathy Diehl
Zeteo Biomedical LLC
+(1) 512-614-0144
zeteo@zeteobiomed.com

*LOGO link for media: https://www.send2press.com/300dpi/20-1117s2p-zeteo-biomedical-300dpi.jpg

NEWS SOURCE: Zeteo Biomedical LLC

To view the original story, visit: https://www.send2press.com/wire/zeteo-biomedical-secures-global-patents-for-nasal-and-ophthalmic-drug-delivery-device-innovations/

Pain Neuromodulation Market to Reach $6.5 Billion by 2030

The market includes spinal cord stimulation (SCS) systems as well as peripheral nerve stimulation (PNS) systems

SAN FRANCISCO, Calif., March 31, 2025 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the newsletter Neurotech Business Report, announced the availability of a new market research report that forecasts the growth of the worldwide market for implanted pain neuromodulation systems. According to the newly published report, “The Market for Implanted Pain Neuromodulation Systems: 2025-2030,” the worldwide market will be $3.37 billion in 2025, growing to $6.49 billion by 2030, which represents a 12% compound annual growth rate. The market includes spinal cord stimulation (SCS) systems as well as peripheral nerve stimulation (PNS) systems. Neurotech Reports estimates that the PNS market will grow at a 29% CAGR between 2025 and 2030.

Image caption: Neurotech Reports recently released its latest forecast on the growth of the market for implanted pain neuromodulation systems, which include spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS) systems.

Major players in the SCS market include Medtronic, Abbott, Boston Scientific, and Nevro, which was recently acquired by medtech manufacturer Globus Medical. The report includes Neurotech Reports editors’ analysis of the impact of this transaction on the competitive landscape of the SCS market. Newer players in the SCS market include Saluda Medical, which pioneered the concept of closed-loop SCS, and European firm Biotronik.

Leading competitors in the PNS space include Curonix, which markets an injectable pain stimulator, SPR, which markets a percutaneous system, Nalu Medical, Bioventus, and Mainstay Medical, which markets a restorative neuromodulation system for treatment of back pain of mechanical origin. Several startup and emerging firms are poised to enter the space in coming years.

The Market for Implanted Pain Neuromodulation Systems: 2025-2030 was authored by the editors of Neurotech Reports, including James Cavuoto, Jeremy Koff, Victor Pikov, and others. Now in its 25th year of publishing, Neurotech Reports is the longest-serving publishing and market-intelligence firm serving the neuromodulation market.

The report includes up-to-date information obtained at the 2025 meeting of the North American Neuromodulation Society, the 2025 JP Morgan Healthcare Conference, and other recent events. Data for the report was obtained from dozens of confidential interviews with key executives in the industry as well as numerous implanters of neuromodulation devices.

“There are a number of market research reports that claim to offer insight on the neuromodulation industry. But neuromodulation industry professionals should ask if they’ve ever seen the authors of those reports at key conferences such as NANS, INS, LSI. Neurotech Reports editors have been covering these events for 25 years and know the key players inside and out,” said James Cavuoto, editor and publisher of Neurotech Reports. “This report draws on our 25 years of reporting on the neuromodulation industry.”

Learn more: https://www.neurotechreports.com/pages/mnmsumm.html

MULTIMEDIA:

Image link for media: https://www.Send2Press.com/300dpi/25-0331-s2p-nrpainmod-300dpi.jpg

NEWS SOURCE: Neurotech Reports

This press release was issued on behalf of the news source (Neurotech Reports), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/pain-neuromodulation-market-to-reach-6-5-billion-by-2030/

SET Enterprises launches 340b covered entity suspicious purchase identification service for pharmaceutical and biological manufacturers

PHOENIX, Ariz. /ScoopCloud/ -- SET Enterprises (set-enterprises.com), a leading independent management consulting firm serving the government pricing compliance needs of life sciences manufacturers, today announced the launch of SPI340B℠. This new service offering identifies specific 340B covered entities that exhibit suspicious purchasing patterns that suggest the entire volume of products purchased from pharmaceutical and biotechnology manufacturers may not be dispensed solely to eligible patients of the covered entity. 340B entities are required to dispense covered outpatient drugs only to a person who is a patient of the entity and are specifically prohibited from reselling the drug to another entity. Reselling discounted 340B drugs or dispensing to a non-patient is known as diversion.

The Health Resource and Services Administration (HRSA) is the governmental agency with oversight of the 340B program. From 2012-2020, HRSA conducted 1,242 audits of 340B covered entities. HRSA found 546 entities that diverted products to non-patients (44.0% of the total) [United States Government Accountability Office report (GAO-21-107), December 2020]. So, the challenge becomes, which 340B covered entities are more likely to be diverting product and should be singled out for further investigation. That is where SET Enterprises' SPI304B℠ comes in. Using proprietary algorithms and models developed working with the Drug Enforcement Administration (DEA), SET's SPI340B℠ service combs through the manufacturer's direct and indirect sales data looking for specific purchasing patterns that signal evidence of a diversionary buying pattern.

These suspicious purchasing patterns were first identified working with the DEA to search for retail pharmacies that were reselling Schedule 2 narcotics on the street. The results were so successful at identifying diversion, the DEA required all of the largest wholesalers to submit their sales data of Schedule 2 narcotics to be monitored for suspicious purchasing activity. SET Enterprises was engaged by a top ten pharmaceutical manufacturer to uncover why chargeback discounts exceeded sales on a deeply discount product sold to doctor's offices. Using enhanced DEA suspicious order monitoring algorithms and models, SET discovered the product was being diverted by physician's offices back to wholesalers to be resold. Further, SET identified which wholesalers were purchasing the product illegally and which specific customers were purchasing the product at a discount, then reselling the product (diversion) back to wholesalers to be resold again generating additional (excessive) chargeback discounts.

What makes product diversion particularly attractive for 340B covered entities is the differential between the price they pay for the product and how much they are reimbursed upon dispensing the product. This pricing spread can be significant as reported by the Community Oncology Alliance which found that "340B hospitals' own self-reported pricing data reveals that they price the top oncology drugs at 4.9 times their 340B acquisition costs" [Examining 340B Hospital Price Transparency, Drug Profits, and Incentives, September 2022]. In many cases, the manufacturers are required to sell 340B products at $0.01 per unit, in which case virtually the entire reimbursement is spread. Instead of guessing who the potential 340B bad actors are, SPI340BSM provides manufacturers with a targeted list of 340B entities whose purchasing patterns signal a greater likelihood of product diversion. This knowledge can significantly increase a manufacturer's ability to reduce revenue leakage with minimal investments.

ABOUT SET ENTERPRISES:

SET Enterprises (S•E•T Enterprises) has been working with large pharmaceutical and vaccine manufacturers for the past 30 years improving their government pricing compliance, automating their pricing calculations, auditing their price submissions, integrating their commercial pricing strategies with the impact on their required regulatory pricing and optimizing their portfolio contracting and pricing strategies.

For more information about the Suspicious Purchasing Identification 340B service, please email SPI340B@set-enterprises.com.

Learn more at: https://set-enterprises.com/

SET Enterprises, a leading independent management consulting firm serving the government pricing compliance needs of life sciences manufacturers, today announced the launch of SPI340B℠. This new service offering identifies specific 340B covered entities that exhibit suspicious purchasing patterns that suggest the entire volume of products purchased from pharmaceutical and biotechnology manufacturers may not be dispensed solely to eligible patients of the covered entity.

Related link: https://set-enterprises.com/

Divergent CRO Announces Launch of New Contract Research Organization

ATLANTA, Ga. /ScoopCloud/ -- Divergent CRO, a leading provider of clinical services to biotech and device companies, is pleased to announce the official launch of its new Contract Research Organization (CRO). This new venture aims to revolutionize the research and development process by offering comprehensive and tailored clinical services to meet the unique needs of the biotech and device industries.

With an unwavering commitment to excellence, Divergent CRO provides a wide range of services, including clinical trial management, regulatory affairs, data management, biostatistics, and medical writing. By leveraging our extensive expertise, we are dedicated to helping our clients accelerate the development of innovative biopharmaceuticals and medical devices.

Our team of highly skilled professionals, including experienced clinical researchers, project managers, and regulatory specialists, is dedicated to delivering the highest standards of quality and efficiency throughout each stage of the clinical trial process. We understand the challenges faced by biotech and device companies and are committed to providing flexible and cost-effective solutions to meet their specific needs.

Divergent CRO is equipped with cutting-edge technology and infrastructure to ensure the smooth execution of clinical trials. Our advanced data management systems and secure facilities ensure the confidentiality and integrity of study data, while our robust quality assurance processes guarantee compliance with regulatory requirements.

"We are thrilled to launch our new Contract Research Organization and partner with biotech and device companies to advance the development of life-changing therapies," said Divergent CRO's Owner-Partners. "Our team is dedicated to delivering exceptional results and providing the highest level of service to our clients. With our expertise and commitment to excellence, we are confident that we can make a significant impact on the success of their clinical programs."

Divergent CRO is now accepting inquiries and is available to discuss collaboration opportunities with biotech and device companies seeking to enhance their clinical research capabilities.

For more information, please visit Divergentcro.com or contact our business development team at Customerservice@divergentcro.com or (888) 342-1447.

About Divergent CRO:

Divergent CRO is a leading provider of clinical services to biotech and device companies. With a focus on innovation and quality, we strive to accelerate the development of life-changing therapies through our comprehensive and tailored clinical services. We thrive on leaving our clients and patients satisfied by improving human health and wellness. Our team of experts is dedicated to delivering exceptional results and providing the highest level of service to our clients. At Divergent CRO, we don't just manage clinical trials; we craft personalized solutions, striving to be the difference by transforming challenges into triumphs in the pursuit of groundbreaking healthcare innovation.

Learn more at: https://divergentcro.com/

Social Links:

LinkedIn Page: https://www.linkedin.com/company/divergentcro/

Instagram: https://www.instagram.com/divergent.cro/

TikTok: https://www.tiktok.com/@divergentcro1

YouTube: https://www.youtube.com/@DivergentCRO

Featured Podcasts:

The Jali Podcast - Melyssa Barrett/DivergentCRO - https://melyssabarrett.com/the-jali-podcast/

Episode Thirty-one - AMY HUTTO, PRODUCTIVITY COACH - https://amyhutto.com/podcast/s1ep30

Divergent CRO, a leading provider of clinical services to biotech and device companies, is pleased to announce the official launch of its new Contract Research Organization (CRO). This new venture aims to revolutionize the research and development process by offering comprehensive and tailored clinical services to meet the unique needs of the biotech and device industries.

Related link: https://divergentcro.com/

Trends in Drug Benefit Design Report Released by Pharmaceutical Strategies Group (PSG)

DALLAS, Texas /ScoopCloud/ -- Pharmaceutical Strategies Group (PSG), an EPIC company, is pleased to announce the launch of its Trends in Drug Benefit Design Report. The report delivers innovative research on the latest trends in the traditional (non-specialty) drug benefit. Sponsored by Rx Savings Solutions, it outlines the complexities of designing and managing the drug benefit and the cost challenges faced by consumers and plan sponsors alike.

KEY HIGHLIGHTS OF THE FINDINGS INCLUDE:

* Plan sponsors are grappling with the potential cost of weight loss drugs.

With respondents divided on weight loss as a lifestyle or chronic condition, 43% cover FDA-approved weight loss medications, and 28% may do so in the next 1-2 years.

"Employers are concerned about affordability, as well as the long-term side effects resulting from chronic use," commented Michael Medel, PharmD, Senior Vice President and Practice Lead Plan Sponsors. "While there is recognition of the positive health benefits of weight loss, the data is lacking today to support any significant cost-offset of those benefits."

* Most plans use more than one type of trend and utilization management program, such as prior authorization and refill too soon limits, but these programs can present challenges.

Growing percentages of respondents cited cost and cumbersomeness as barriers to utilization management programs. Two-thirds of respondents wanted more transparency and accountability in these programs, and over half expressed interest in new offerings for tracking and controlling utilization.

* Major advancements have been made in gene and cell therapies over the past 5 years, and as the pace of change increases, interest in financial protection products is growing.

Nearly all (91%) respondents have heard of gene therapy financial protection products. While just 7% currently use these products, nearly half are considering it.

"With a robust cell and gene therapy pipeline, plan sponsors are seeking ways to mitigate the financial risk these expensive therapies present while also ensuring access for their members. Although few are currently using cell and gene therapy financial protection products, many are considering it. This will be an interesting trend to watch in the coming years," noted Morgan Lee, PhD, MPH, CPH, Senior Director, Research & Strategy, PSG.

* Plan sponsors recognize the need to reduce wasteful drug spend.

A little over half of plans (53%) take steps to identify and reduce wasteful spend in the formulary; that percent rising to 75% when isolating the data to health plans. Blocks, exclusions, and use of programs and reporting from their PBM are among the most common steps they take to address this problem.

* The monetary impact of cost-sharing strategies on consumers has spurred a focus on transparency.

The promotion of cost-sharing transparency tools to help members manage expenses continues to rise, from 28% in 2018 to 63% in 2023.

"We are honored to once again sponsor this insightful report, which highlights the importance for plan sponsors to evolve the pharmacy benefit," said Michael Rea, PharmD, Founder and CEO of Rx Savings Solutions (RxSS). "This year, there is a noticeable undercurrent of change in the market. Consumers and patients whose share of prescription drug costs continue to grow are searching for relief and turning to sources both within and outside of the traditional drug benefit. It's a goal all of us in the pharmacy benefit ecosystem to help advance the benefit in ways that produce greater access and affordability, all while controlling spend."

Since the inception of this report, the drug benefit has become more intricate to design and manage. With many new drugs coming to market, decisions around program structure, formulary design, cost sharing, and trend management become increasingly challenging and important. This report helps benefit leaders identify trends and future possibilities so they can adjust as appropriate around these factors and more.

Download the "Trends in Drug Benefit Design" Report: Trends in Rx Benefit Design | Rx Savings Solutions (rxss.com): https://rxss.com/benefit-design-report-2023/

About the 2023 Trends in Drug Benefit Design Report:

The Trends in Drug Benefit Design Report provides in-depth insights into traditional (non-specialty) drug benefit trends and strategies and focuses on drug benefit design for the 2023 benefit year among employers, union/Taft-Hartley, and health plan respondents. The survey sample informing this report included 180 benefits leaders. Issues specific to specialty drugs are included in a separate report - Trends in Specialty Drug Benefits. This report as well as prior annual reports conducted by PSG can be found at https://www.psgconsults.com/research.

About Pharmaceutical Strategies Group (PSG):

Pharmaceutical Strategies Group, an EPIC company, relentlessly advocates for clients as they navigate complex and ever-changing drug cost management challenges. PSG functions as a strategic partner through industry-leading intelligence and technologies to realize billions of dollars in drug cost savings for clients every year. Learn more: https://www.psgconsults.com/

About Rx Savings Solutions - Report Sponsor:

Rx Savings Solutions ("RxSS"), part of McKesson Corporation, works on behalf of everyone who takes prescription drugs and the health plans and employers who cover them. Founded by a former retail pharmacist, RxSS helps members reduce out-of-pocket prescription costs and a health plan's pharmacy spend. The solution layers on top of an existing pharmacy benefit and analyzes individual claims to identify and present cost-saving alternatives to each member. Our member engagement platform notifies members proactively anytime they have prescription savings available. Visit https://rxss.com for more information.

Pharmaceutical Strategies Group (PSG), an EPIC company, is pleased to announce the launch of its Trends in Drug Benefit Design Report. The report delivers innovative research on the latest trends in the traditional (non-specialty) drug benefit. Sponsored by Rx Savings Solutions, it outlines the complexities of designing and managing the drug benefit and the cost challenges faced by consumers and plan sponsors alike.

Related link: https://www.psgconsults.com/

PSG Announces Release of Highly Anticipated ‘Trends in Specialty Drug Benefits Report’

DALLAS, Texas /ScoopCloud/ -- Pharmaceutical Strategies Group (PSG), an EPIC company, is pleased to announce the release of its annual Trends in Specialty Drug Benefits report. Delivering visibility into the complexity of the specialty drug landscape, it offers detailed intelligence through proprietary research.

Specialty drug costs have continued to push the boundaries in terms of complexity and affordability. The complicated landscape must consider many variables, such as multiple dispensing channels, dual payment methods, and site of care. This report takes a detailed look into what plan sponsors are facing as they make decisions relative to specialty drug benefit plan design.

Alternative funding continues to be a hot topic as plans explore strategies to help offset the high cost of specialty drugs.

"As plans continue to seek ways to offset specialty drug costs, the market is divided as to whether alternative funding is a positive option or a detriment," commented Michael Lonergan, RPh, PSG President. "Affordability of specialty drugs for plans and members is driving this interest, while there is a concern about sustainability in these models."

Integrated pharmacy and medical claims data for managing specialty drugs remains essential.

"Total cost of care is a key concern, and payers rely on reporting that details how well specialty drugs are performing through the insights of integrated data. However, the challenge is in tracking clinical efficacy," observed Morgan Lee, PhD, MPH, CPH, Senior Director, Research and Strategy.

Affordability of cell and gene therapies will likely be a significant payer challenge in coming years.

"As the cost of specialty drugs continues to increase, some health plans and fewer employers have explored the use of value-based contracting (VBC), a performance-based reimbursement agreement. Rare disease treatments that are being targeted by cell and gene therapies will drive future spending," noted Renee Rayburg, RPh, Vice President, Specialty at PSG. "VBCs represent an effort into finding strategies for keeping costly specialty drugs accessible and affordable."

KEY FINDINGS FROM THE REPORT INCLUDE:

* Gene Therapies: While just 24% of respondents have had a gene therapy patient, 81% expect affordability of gene therapies to be a moderate or major challenge in the next 2-3 years.

* Alternative Funding: 14% of employers and 7% of health plans use alternative funding models, and 14% of employers and 33% of health plans are exploring their use. However, 68% of respondents viewed these models as not at all or slightly sustainable.

* Value-based Contracting: Only 12% of respondents report using value-based contracting for specialty drugs. The need for additional evidence, difficulty agreeing on and tracking outcomes, and lack of resources and buy-in were all cited as key barriers to adoption.

* Specialty Rebates: Nearly all plans receive specialty drug rebates under the pharmacy benefit, but health plans are more likely than employers to receive rebates under the medical benefit (66% vs. 27%).

Additional topics covered in the report include increasing usage of new-to-market formulary blocks, interest in site of care programs, prior authorization tracking and reporting, and use of strategies related to biosimilars.

Download the Trends in Specialty Drug Benefits Report and register for the 5/10/23 webinar here: https://www.psgconsults.com/2023specialtybdr-webinar

About the Trends in Specialty Drug Benefits Report

PSG has been researching and reporting on drug benefit design for over 10 years. The report takes an in-depth look at trends and best practices in specialty drug benefit design through the lens of comprehensive questions and responses from over 180 employers, health plans, and labor unions.

About Pharmaceutical Strategies Group (PSG)

Pharmaceutical Strategies Group, an EPIC company, relentlessly advocates for clients as they navigate complex and ever-changing drug cost management challenges. PSG's innovative drug management solutions, including Artemetrx(R) - PSG's proprietary industry-leading software for integrated drug management, deliver actionable insights with exceptional financial and clinical value. PSG functions as a strategic partner through industry-leading intelligence and technologies to realize billions of dollars in drug cost savings for clients every year. Learn more: https://www.psgconsults.com/

Pharmaceutical Strategies Group (PSG), an EPIC company, is pleased to announce the release of its annual Trends in Specialty Drug Benefits report. Delivering visibility into the complexity of the specialty drug landscape, it offers detailed intelligence through proprietary research. PSG has been researching and reporting on drug benefit design for over 10 years.

Related link: https://www.psgconsults.com/

NEW PRODUCT LAUNCH: Pharmaceutical Strategies Group (PSG) Announces Artemetrx Extend – Revolutionary Drug Management Reporting Tool Offers Powerful User Insights

DALLAS, Texas /ScoopCloud/ -- Artemetrx®, the industry's most preeminent platform for integrated drug cost management, is now even more robust with the launch of its new module, Artemetrx Extend™. With greater insights and analytics, Artemetrx Extend is a custom reporting tool that provides unparalleled data access through its user-friendly platform.

"Artemetrx delivers swift and easy access to valuable drug management insights. With Artemetrx Extend, our clients will be able to further tap into the rich integrated dataset of the Artemetrx platform," said Libby Johnson, PSG Chief Data and Analytics Officer. "Artemetrx Extend continues our long legacy of client advocacy and innovation, as the industry's best keeps getting better."

Can your organization quickly get its data-driven questions answered? Most plans get bogged down waiting for custom analytics when Artemetrx can respond in seconds. The major capabilities now available within Artemetrx Extend, through powerful filtering and drill downs, include the ability to:

* Determine how many members have medical claims associated with a diagnosis for a specific group

* Analyze the specific diagnoses that a particular drug is prescribed to treat for a population based on claims history

* Model the financial impact of switching from one preferred medication to another

* View spend and trend statistics on all drugs (specialty/non-specialty, medical/pharmacy) or search based on National Drug Code, Healthcare Common Procedure Coding System, or drug name

There are two versions of Artemetrx Extend available: Base Access is available for all users, and Power User Access is optional, allowing for custom report and dashboard building and the ability to save and share reports.

Artemetrx is a proprietary industry-leading web-based software for integrated drug management developed by Pharmaceutical Strategies Group. Artemetrx Extend is the latest in a series of innovations on the Artemetrx platform.

Learn more about how Artemetrx Extend: https://link.psgconsults.com/Artemetrx.Extend

About Artemetrx®

Artemetrx is a proprietary SaaS platform developed by Pharmaceutical Strategies Group (PSG), an EPIC company. As one of the first technology solutions in the market to integrate pharmacy and medical claims data for specialty drug cost management, Artemetrx continues to provide market-leading specialty drug insights to payers. It delivers unparalleled intelligence and line-of-sight into serious challenges perpetuating out-of-control drug costs and compromised patient outcomes.

More information: https://www.psgconsults.com/discoverartemetrx

About Pharmaceutical Strategies Group (PSG)

Pharmaceutical Strategies Group, an EPIC company, relentlessly advocates for clients as they navigate complex and ever-changing drug cost management challenges. PSG's innovative drug management solutions, including Artemetrx®, deliver actionable insights with exceptional financial and clinical value. PSG functions as a strategic partner through industry-leading intelligence and technologies to realize billions of dollars in drug cost savings for clients every year.

More information: https://www.psgconsults.com/

Artemetrx®, the industry's most preeminent platform for integrated drug cost management, is now even more robust with the launch of its new module, Artemetrx Extend™. With greater insights and analytics, Artemetrx Extend is a custom reporting tool that provides unparalleled data access through its user-friendly platform.

Related link: https://www.psgconsults.com/

Kalyagen Announces Attendance and Speaking Engagement at 8th Annual Biohacking Conference

AUSTIN, Texas /ScoopCloud/ -- Kalyagen is pleased to announce that it will be attending and its founder, Christian Drapeau, will be speaking at the upcoming 8th Annual Biohacking Conference. The conference, which is completely sold out, will be held September 15-17 at The Beverly Hilton in Beverly Hills, California.

"The Biohacking Conference will be an ideal opportunity to introduce STEMREGEN directly to an audience whose core focus is to tap into the body's innate ability to repair," said Christian Drapeau. "We are eager to meet and collaborate with the leaders of the biohacking movement."

STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM). Ingredients in STEMREGEN® have been investigated in more than eight studies for their effect on stem cell function, of which five were randomized, double-blind, placebo-controlled human clinical trials. STEMREGEN® has wide application in anti-aging and overall health maintenance.

"The link between a lower number of circulating stem cells and the development of age-related diseases has been well studied with numerous degenerative conditions, including diabetes, cardiovascular diseases, atherosclerosis, Alzheimer's disease, rheumatoid arthritis, pulmonary diseases, erectile dysfunction, and kidney disease," continued Mr. Drapeau. "From a therapeutic standpoint, increasing the number of circulating stem cells has been documented to enhance tissue repair or improve the course of disease formation in many degenerative conditions and overall health and well-being."

About Kalyagen:

Austin-based Kalyagen® was founded by Christian Drapeau, author of the bestseller Cracking the Stem Cell Code. Kalyagen® is a leader in the research and development of natural products aimed at supporting stem cell function of the body. Stem cells constitute the natural repair system of the body, and stem cell enhancers have been documented to strongly contribute to improving health and quality of life. STEMREGEN® is the first stem cell enhancer product developed by Kalyagen®. STEMREGEN® is a unique blend of proprietary plant-based extracts documented to support Endogenous Stem Cell Mobilization and provide other health benefits.

For more information, please visit our website: https://www.kalyagen.com/

CONTACT:

Biomics, LLC (dba Kalyagen®)

Herbert Dogan, Chief Marketing Officer (310-433-8072)

hgd@kalyagen.com

Social media: @kalyagen #kalyagen #christiandrapeau #stemcellchristian #stemregen #stemcells #stemregeneffect #stemthetideoftime #stemthetide #biohacking

Disclaimer: None of the statements contained in this press release have been evaluated by the U.S. Food and Drug Administration. The products and information in the release are not intended to diagnose, treat, cure or prevent any disease.

Kalyagen is pleased to announce that it will be attending and its founder, Christian Drapeau, will be speaking at the upcoming 8th Annual Biohacking Conference. The conference, which is completely sold out, will be held September 15-17 at The Beverly Hilton in Beverly Hills, California.

Related link: https://www.kalyagen.com/

Zeteo Biomedical Introduces OrionMRQ™ Nasal Delivery Device for Vaccines

PFLUGERVILLE, Texas /ScoopCloud/ -- Zeteo Biomedical LLC announced today the availability of the ZEOx1 OrionMRQ™ nasal drug and vaccine delivery device. Zeteo's latest innovative delivery device provides pharmaceutical and biotech companies developing drugs, peptides, proteins, monoclonal antibodies and vaccines with precise, metered unit dose systemic delivery via the nasal route.

Nasal administration provides needle free, rapid systemic uptake into the body via the nose. Nasal delivery of vaccines can invoke a fast local immune response in the respiratory track, which is frequently the primary route of infection for contagious pathogens such as pandemic flu or coronavirus. The ZEOx1 OrionMRQ™ device is intuitive to use, enabling either patient self-administration or administration by caregivers with configurations available for both adults and children.

The OrionMRQ reloadable nasal delivery device has the capability to store up to four unit doses in the on-board storage compartment. The device is compact making it easy to carry in a pocket or purse. Zeteo intranasal delivery devices incorporate novel packaging technology utilizing a Form Fill Seal (FFS) flexible foil, packaging the drug or vaccine in a unit dose blister reducing the cost and eliminating the supply chain constraints of glass vials.

ZEOx1™ blister packaging provides exceptional barrier properties to protect the drug or vaccine during storage and transport and can be stored at room temperature, refrigerated or frozen storage conditions. The ZEOx1™ packaging technology is commercially scalable to produce millions of doses per day; a critically important requirement for rapid, cost effective deployment of vaccines and medical countermeasures to global populations.

About Zeteo Biomedical LLC:

Zeteo Biomedical™ is a biomedical device technology company based in Austin, Texas. Zeteo provides patient-centric delivery device technology, drug/device combination product development services and fill/finish packaging technology for pharmaceuticals, biopharmaceuticals, biologics and botanicals for intranasal, nose-to-brain, ophthalmic, sublingual, and animal care product applications.

For more information, please visit the Zeteo website at: https://www.zeteobiomed.com/

Zeteo Biomedical LLC announced today the availability of the ZEOx1 OrionMRQ™ nasal drug and vaccine delivery device. Zeteo's latest innovative delivery device provides pharmaceutical and biotech companies developing drugs, peptides, proteins, monoclonal antibodies and vaccines with precise, metered unit dose systemic delivery via the nasal route.

Related link: https://www.zeteobiomed.com/

Oral Vaccine Boosts COVID Immunity: study conducted on nonhuman primates is published in the journal Vaccine

ROCHESTER, Minn. /ScoopCloud/ -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine accessible at http: https://www.sciencedirect.com/science/article/pii/S0264410X21016716

The article describes the evaluation of an oral COVID-19 vaccine built on the vesicular stomatitis virus (VSV) platform. Oral administration of the VSV based vaccine induced antibodies that could neutralize SARS-CoV-2, the virus that causes COVID-19. More importantly, the novel oral formulation powerfully boosted the levels of neutralizing antibodies against SARS-COV-2 in previously vaccinated monkeys. The oral vaccine was shown to be safe and did not cause clinically significant adverse effects.

"By tweaking the way we generate the VSV-SARS vaccine, we created a new oral formulation that worked remarkably well to boost virus neutralizing antibody titers when administered into the cheek pouches of cynomolgus macaques whose immunity was waning after they had been primed with an intramuscular vaccine," stated Kah-Whye Peng, Ph.D., Chief Technical Officer of Vyriad, and first author of this publication. "Oral dosing is convenient and more likely to be accepted by people who are reluctant to receive yet another intramuscular injection to boost their immunity."

The COVID-19 pandemic is not over and there is a continued need to deliver vaccines to a much of the world's population. An effective oral vaccine/booster has the potential to dramatically improve vaccine uptake rates by addressing some of the key barriers to effective deployment such as logistics of distribution to remote populations, fear of needles, and administration to young children.

"We are excited by these groundbreaking findings. Vyriad has cGMP manufacturing capabilities and is running clinical trials using an engineered VSV for cancer therapy. We are therefore actively seeking partnership to help bring this promising platform to human testing," stated Stephen J Russell, M.D., Ph.D., Chief Executive Officer of Vyriad.

The publication is a collaboration between researchers at Vyriad, Imanis Life Sciences, Regeneron Pharmaceuticals, and the University of Minnesota.

About Vyriad, Inc.

Vyriad is a clinical-stage company developing virus-based therapeutics, focusing initially on proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. Founded by scientists at Mayo Clinic and the University of Miami, Vyriad is working with VSV, measles and picornavirus platforms, programming their viruses to selectively attack cancer cells, thereby igniting antitumor immune responses that can complete the process of tumor destruction and prevent disease recurrence.

Our lead platform, derived from vesicular stomatitis virus (VSV), is being evaluated in ongoing Phase 1-2 clinical trials addressing multiple cancer types. Vyriad and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have a well-established broad-based strategic agreement for the discovery and development of new oncolytic virus treatments for cancer leveraging Vyriad's VSV platform and Regeneron's PD-1 inhibitor Libtayo® (cemiplimab-rwic) as well as its unmatched antibody discovery capabilities. Vyriad is a privately held company based in Rochester, Minnesota.

For more information, visit https://vyriad.com/.

Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine.

Related link: https://vyriad.com/

Myrio Therapeutics and Pure MHC, LLC Announce Research Collaboration to Develop Novel, Targeted Antibody-Based Cancer Therapies

OKLAHOMA CITY, Okla. /ScoopCloud/ -- Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC's proprietary offering of MHC peptide targets for oncology with Myrio's revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer.

The cancer therapies resulting from this collaboration will represent a unique synergism: Myrio's ReD platform is differentiated in its ability to routinely identify antibodies that bind to peptides from intracellular proteins presented on the cell surface by major histocompatibility complex (MHC), and Pure MHC is a world-leader in the identification and validation of peptide/MHC (pMHC) targets. Antibodies to next generation pMHC oncology targets may provide more efficacious therapies, particularly for solid tumors, while minimizing off-target effects for patients.

Researchers at both companies expressed excitement at the prospect of combining these innovative approaches:

"The speed and flexibility of Myrio's ReD platform enables the generation of robust antibody-based therapies against challenging targets like pMHC with high affinity and specificity," said Myrio's CEO Pete Smith. "Pure MHC's curated pMHC targets are an excellent fit for our platform and substantially de-risk downstream development."

Pure MHC's Chief Scientist, William Hildebrand, PhD shared this enthusiasm, "Pure MHC is dedicated to the identification of pMHC complexes distinct to cancer and absent from healthy tissues. Peptide/MHC complexes for several oncology indications have been identified by Pure MHC as present on tumors yet absent from healthy tissue, and we are excited for Myrio to deploy their cutting-edge technology to engineer antibodies that recognize our targets with great specificity."

From a business perspective, these therapeutic candidates will bolster Myrio's existing portfolio of in-house assets while providing Pure MHC access to a powerful antibody platform that enables multiple therapeutic pipelines.

"Myrio's platform is not just an outstanding scientific fit, the collaboration represents a unique and exciting way for Pure MHC to deploy its novel target assets strategically," said Kris Looney, President of Pure MHC. "As we continue to provide targets from our pipeline to the market via more traditional partner licensing models, we felt the time was right to also establish our own therapeutic pipeline and have found exactly the collaborator we need in Myrio."

Pete Smith agreed, "With the close alignment of both scientific and business objectives between our two companies, a partnership between Myrio and Pure MHC just makes so much sense. We are excited about its potential."

The companies expect the collaboration to yield therapeutic candidates within the next twelve months.

About Myrio Therapeutics

Myrio Therapeutics is driving a new frontier of antibody-based therapies as the company's Retained Display(tm) (ReD) antibody platform offers identification of highly specific human antibodies that bind to peptide-MHC complexes. Myrio's antibodies can readily be converted into multispecific, CAR-T or other formats, dramatically increasing the target landscape for these modalities. Visit: http://www.myriotx.com/

About Pure MHC

Pure MHC, LLC is a platform technology company funded and managed by Emergent Technologies, Inc. with expertise in disease-specific target identification and validation as well as immunotherapeutic drug development for cancer, infectious disease, and autoimmune diseases. The Pure MHC target discovery technology was developed by Chief Scientist William Hildebrand, Ph.D., of the University of Oklahoma Health Science Center. For more information, visit: https://puremhc.com/

About Emergent Technologies

Emergent Technologies, Inc. is an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: http://www.etibio.com/

Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC's proprietary offering of MHC peptide targets for oncology with Myrio's revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer.

Related link: https://puremhc.com/

Geminid Systems Unveils Pharmalite CRM to Boost Remote Engagement of Pharma Field Teams

REDWOOD CITY, Calif. /ScoopCloud/ -- Geminid Systems, Inc. today announced the global rollout of a SaaS super-app that aims to improve pharmaceutical operations by helping field teams easily overcome challenges arising from the ongoing COVID pandemic.

In conjunction with the product's worldwide release, subscriptions to the app are available at discounted pricing through Jan. 31, 2022.

"Pharmalite CRM is an all-in-one app that enables pharma sales and medical field teams to much more effectively perform, track, and analyze the complex tasks involved in working with existing and prospective healthcare providers," said Guru Karur, VP Product Strategy.

"It's essential for pharma companies," Karur continued, "to have field teams that can communicate better, faster, and more impactfully with providers by use of digital transformation technologies. Companies are finding it difficult now in this pandemic environment to meet patient needs, satisfy regulatory compliance requirements, and reach business objectives."

Karl Gunst, senior product lead, agreed. "The pandemic is making it difficult to build effective field teams. It's more difficult because the environment has changed from face-to-face to remote interactions. Existing solutions have failed to meet the new remote needs."

According to Karur, a potent attribute of Pharmalite CRM is its ability to create fully regulatory-compliant recordings and paper-trails for each interaction between the field teams and health care providers, whether remote or otherwise.

Gunst added that Pharmalite CRM eliminates the need to use as many as a dozen separate apps to cover all the bases. "Pharmalite CRM consolidates within a single app the functionalities to permit training, compliance, analytics, compensation, and more," he said.

"Most CRM solutions lack built-in analytics and advanced insights," Karur said. "Pharmalite CRM fills this gap with excellent support for startup, midlife, and fully mature pharmaceutical companies alike-especially those that urgently need to become more agile."

Pharmalite CRM was in development and beta testing for three years prior to today's debut, but the super-app already is in use by a number of pharmaceutical companies, Gunst revealed.

Company officials predict Pharmalite CRM will quickly emerge as a formidable rival to the industry's current top-selling CRM products.

Said Karur: "We in fact believe Pharmalite CRM will eventually overtake the competition as more and more pharmaceutical teams subscribe to our solution and discover its advanced capabilities and actionable AI-driven insights, which are made possible by highest compliance, performance, and scalability features."

To learn more about Pharmalite CRM, please visit https://www.pharmalitecrm.com/.

ABOUT GEMINID SYSTEMS

Redwood City, California-based Geminid Systems, Inc. is the maker of Pharmalite CRM, currently the only all-in-one pharma SaaS product with applications for sales, medical, market access, as well as management and executive teams. In developing Pharmalite CRM, Geminid harnessed mobile and web technologies to its extensive cloud technologies experience, thereby permitting creation of a fully integrated package of productivity-enhancing, process-simplifying tools designed for unparalleled ease of use.

Geminid Systems, Inc. today announced the global rollout of a SaaS super-app that aims to improve pharmaceutical operations by helping field teams easily overcome challenges arising from the ongoing COVID pandemic.

Related link: https://geminidsystems.com/

iCell Gene Therapeutics Announces cCAR-T Clinical Publication in the Stem Cell Reviews and Reports Journal

STONY BROOK, N.Y. /ScoopCloud/ -- iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, today announced the publication of their clinical study utilizing cCAR T-cell immunotherapy to successfully treat a patient with lupus. Their CAR is directed against CD19 and BCMA surface proteins generating a cCAR with dual expression of CD19 and BCMA CAR molecules. Their cCAR is one of a kind in the family of engineered CAR T-cells researchers are studying.

Their report "Treatment of Systemic Lupus Erythematosus Using BCMA-CD19 Compound CAR" published on August 30, 2021, shows the clinical success of cCAR in treating a patient with Systemic Lupus Erythematosus (SLE).

According to Dr. Yupo Ma, founder of iCell Gene Therapeutics, "After a single infusion of CD19-BCMA cCAR the patient achieved undetectable levels of autoantibodies that mediate SLE, successfully treating the patient's SLE for 2 years without the need for additional medications."

The publication is available online at https://doi.org/10.1007/s12015-021-10251-6.

About SLE

Systemic lupus erythematosus (SLE) is an antibody-mediated autoimmune disease, in which autoantibodies attack its own tissues, resulting in widespread tissue damage in the affected organs including kidneys, lungs, joints, brain and blood vessels. According to the Lupus Foundation of America, it estimates that 1.5 million Americans, and at least five million people worldwide, have a form of lupus.

About CD19-BCMA cCAR Therapy

iCell has developed a novel compound Chimeric Antigen Receptor (cCAR)approach. In this approach, the cCAR T cells express two distinct and fully functional CAR molecules, one that targets the molecule CD19 present on B cells and one that targets BCMA, which is present on plasma cells. In their recently published paper, researchers have shown that this cCAR led to rapid and dramatic decreases in B cell levels and levels of "autoantibodies" (antibodies that attack the body's own cells) in a patient with SLE.

As B cells are part of the normal immune system, it is preferable that the elimination of B cells be temporary. After 9 months of B cell depletion, the patient's B cells returned to normal. Importantly, the levels of autoantibodies remained undetectable. Based on these results, the researchers concluded that cCAR effectively "reset" the antibody-producing populations. In this "reset," the problematic cell populations were removed, leaving behind a fresh, clean slate. From this, new B cells and plasma cells were eventually formed, which did not have the same autoantibody-producing properties. Because of this, the patient has not had further lupus symptoms despite receiving no additional medications for over 2 years.

Given the prevalence of antibody-mediated disorders, this cCAR may prove useful for a variety of different medical conditions.

Sjögren's Syndrome, autoimmune hemolytic anemia, neuromyelitis optica spectrum disorder, celiac disease, type 1 diabetes, inflammatory bowel disease, rheumatoid arthritis, psoriasis, and multiple sclerosis all incorporate autoantibody formation in disease pathogenesis. Additionally, organ rejection following transplantation may be mediated by antibodies. By "resetting" the immune system prior to organ transplantation, this antibody-mediated rejection may be avoided. More research is needed on the long-term efficacy and safety of this treatment, but future applications of cCAR has a large window of opportunity.

About iCell Gene Therapeutics

iCell Gene Therapeutics, located in Stony Brook, New York, is a clinical-stage biopharmaceutical company developing first-in-class chimeric antigen receptor engineered cells. Their main focuses are on autoimmune disorders, AML, and T-cell malignancies. Their current clinical trials utilize their CARvac, T-cell targeted CARs, cCARs and non-gene edited universal CARs engineered as treatments for cancer, organ rejections and autoimmune diseases. These studies are ongoing in the US and China for their use.

For more information, please visit http://icellgene.com/

CONTACT:
Media and Investors
Kevin Pinz
Tel: (631) 538-6218
Kevin.pinz@icellgene.com

RELATED LINKS:

https://www.lupus.org/resources/how-many-people-have-lupus-in-the-united-states

https://www.lupus.org/resources/what-is-lupus

iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, today announced the publication of their clinical study utilizing cCAR T-cell immunotherapy to successfully treat a patient with lupus.

Related link: http://icellgene.com/

Kalyagen Announces Release of Free eBook on How to Optimize Health Using Stem Cells

AUSTIN, Texas /ScoopCloud/ -- Kalyagen® has announced the release and availability of a free eBook, "The Stemregen Effect - Tapping into the Power of Your Own Stem Cells," which provides an overview of how stem cells are the body's repair system and how STEMREGEN®, a natural stem cell enhancer, has been documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).

"Supporting stem cell physiology is a new paradigm in health and wellness," said Christian Drapeau, CEO and Chief Scientist of Kalyagen®. "The latest scientific evidence indicates that this may very well be the best strategy to assist the body in regaining and maintaining optimal health."

The link between a lower number of circulating stem cells and the development of age-related diseases has been well-studied with numerous degenerative conditions, including diabetes, cardiovascular diseases, atherosclerosis, Alzheimer's disease, rheumatoid arthritis, pulmonary diseases, erectile dysfunction, and kidney disease. Increasing the number of circulating stem cells has been documented to enhance tissue repair or improve the course of disease formation in cases of acute myocardial infarction and many other degenerative conditions.

"Kalyagen has been inundated with questions regarding the stem cell repair system and how STEMREGEN naturally helps the body to release stems cells," said Herbert Dogan, CMO of Kalyagen®. "We are pleased to announce the release of our new publication which helps to answer all of these questions."

The eBook is available for download for free at https://www.kalyagen.com/the-stemregen-effect/.

STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to support ESCM and increase the number of circulating stem cells, supporting the natural ability of the body to repair and stay healthy. Ingredients in STEMREGEN® have been investigated in more than eight clinical studies for their effect on stem cell function, of which five were randomized, double- blind, placebo-controlled human clinical trials. STEMREGEN® has wide application in antiaging and overall health maintenance.

About Kalyagen

Kalyagen® was founded by Christian Drapeau, author of the bestseller Cracking the Stem Cell Code. Kalyagen® is a leader in the research and development of natural products aimed at supporting stem cell function of the body. Stem cells constitute the natural repair system of the body, and stem cell enhancers have been documented to strongly contribute to improving health and quality of life. STEMREGEN® is the first product developed by Kalyagen®. STEMREGEN® is a unique blend of proprietary plant-based extracts documented to support Endogenous Stem Cell Mobilization and provide other health benefits.

For more information, please visit our Website: https://www.kalyagen.com/

MEDIA CONTACT:

Biomics, LLC (dba Kalyagen®)

Herbert Dogan, Chief Marketing Officer (310-433-8072), hgd@kalyagen.com

Social media: @kalyagen #stemthetideoftime #stemthetide #thestemregeneffect

Disclaimer: None of the statements contained in this press release have been evaluated by the U.S. Food and Drug Administration. The products and information in the release are not intended to diagnose, treat, cure or prevent any disease.

Kalyagen® has announced the release and availability of a free eBook, "The Stemregen Effect - Tapping into the Power of Your Own Stem Cells," which provides an overview of how stem cells are the body's repair system and how STEMREGEN®, a natural stem cell enhancer, has been documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).

Related link: https://www.kalyagen.com/

Live-Online C. diff. Symposium developed to support and guide patients, families, and caregivers through a C. difficile illness

TAMPA, Fla. /ScoopCloud/ -- The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, July 16, 2021, from 1 to 3 p.m. EDT. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection (CDI) in addition to those who are recovering or who have experienced CDI recurrences. The patients, family members, and caregivers will all benefit from the information and up-to-date data presented.

Presenters are among some of the top C diff. thought leaders and include healthcare professionals, practitioners, and educators who are helping to change the way individuals maneuver through a C. difficile infection, worldwide.

Unlike other presentations on this topic, C. diff. Survivors will share their C. diff. infection journeys to provide a real-world perspective on the patient experience. Other topics addressed will include creating a culture for patient-centered care, C. diff. innovations, diagnostics, research, environmental safety, clinical trials, and studies, C diff. in pediatric patients and more.

To register for this global live-online event, visit: https://cdifffoundation.org/patient-family-caregiver-symposium-july-16-2021/

About Clostridioides difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile, C. diff., is one of the most common cause and leading healthcare-associated infection in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20 percent, the C Diff Foundation believes that the annual incidence in the U.S. approaches 600,000.

About Seres Therapeutics

Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome.

It reported positive, topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI).

For more information: https://www.serestherapeutics.com/

About the C Diff Foundation

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide.

For more information: https://cdifffoundation.org/

Follow C Diff Foundation:

Twitter @cdiffFoundation #cdiffpatientfamilycaregiver #cdiff2021 #cdiffwalks2021

C Diff Foundation(TM) is a trademark of the C Diff Foundation, established 2012 in the U.S.

The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, July 16, 2021, from 1 to 3 p.m. EDT. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection (CDI) in addition to those who are recovering or who have experienced CDI recurrences.

Related link: https://cdifffoundation.org/

Pure MHC, LLC Announces Launch of its Peptide HLA Immunotherapy Data Resource following Collaboration with LifeNet Health

AUSTIN, Texas /ScoopCloud/ -- Pure MHC, LLC, a target discovery and development company, today announced the launch of its Peptide HLA Immunotherapy Data Resource ("PHIDR"), built through its collaboration with a trusted provider of transplant solutions and a leader in regenerative medicine, LifeNet Health.

The PHIDR healthy tissue database and repository will guide T Cell Receptor (TCR)-based immune therapy development to disease-specific targets by enabling developers to identify HLA/peptide complex targets found on healthy tissues. By screening potential target candidates against PHIDR, developers can confidently select, qualify, and focus efforts on those biomarker targets that minimize off-target or bystander effects.

The PHIDR database is representative of the full healthy human immunopeptidome as it includes HLA/peptide complexes expressed on multiple tissue samples from all over the body, with a focus on the vital organs. In addition to the peptide database, PHIDR includes a repository of matched cryopreserved tissue samples that enable complimentary orthogonal target validation techniques, including proteomics-based target quantification, genomics, and transcriptomics, on an as-needed basis.

For nearly 40 years, LifeNet Health has advanced medicine through the life-changing power of organ and tissue donation. Thanks to selfless donors, scientific discovery is advanced.

LifeNet Health LifeSciences has accelerated preclinical research and discovery through its growing portfolio of primary human cells and biospecimens for solutions that expedite research and allow the scientific community to develop and enhance new, safe therapies and medical breakthroughs.

"We are excited to offer access to the PHIDR database and repository to collaborators through our Pure MHC Solutions contract research arm," said Pure MHC President Kris Looney. "We could not have successfully built this resource without our collaborators at LifeNet Health. To be able to develop such a valuable resource for therapeutic development aligns nicely with LifeNet Health's mission to help patients live longer, healthier, and enjoy more active lives."

"We are proud to partner with Pure MHC and congratulate them on achieving success in their research efforts. Thanks to selfless donors, LifeNet Health is able to offer partners more than 40 types of biospecimens for research with over 200 protocols in place to meet the individual needs of researchers advancing scientific discovery," said Louis Dias, Vice President and General Manager of LifeNet Health LifeSciences. "The LifeNet Health LifeSciences team provides access to rare patient disease populations and enables researchers to unlock discoveries faster and with greater precision - offering the hope of new therapies to patients in need."

About Pure MHC

Pure MHC, LLC is a platform technology company funded and managed by Emergent Technologies, Inc. with expertise in disease-specific target identification and validation as well as immunotherapeutic drug development for cancer, infectious and autoimmune diseases and allergy. The Pure MHC target discovery technology was developed by Chief Scientist William Hildebrand, Ph.D., of the University of Oklahoma Health Sciences Center. Visit: www.puremhc.com

About LifeNet Health LifeSciences

LifeNet Health LifeSciences is an innovative leader, trusted collaborator, and reliable solutions provider - committed to advancing science, accelerating discovery, and optimizing outcomes. Leading the way in human in vitro biology, LifeSciences' game-changing innovations, currently under development, include models for the metabolic disease and oncology therapeutic areas and their related tools. For more information, go to www.LNHLifeSciences.org.

About Emergent Technologies

Emergent Technologies, Inc. is an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: www.etibio.com

Pure MHC, LLC, a target discovery and development company, today announced the launch of its Peptide HLA Immunotherapy Data Resource ("PHIDR"), built through its collaboration with a trusted provider of transplant solutions and a leader in regenerative medicine, LifeNet Health.

Related link: https://puremhc.com/

Pure Transplant Solutions Announces Collaboration with the University of Alabama at Birmingham to Develop Memory B Cell-Directed Diagnostics for HLA-Sensitized Patients

BIRMINGHAM, Ala. /ScoopCloud/ -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with The University of Alabama at Birmingham (UAB), a leading institution in transplant research, to develop a new class of transplant diagnostics aimed at the detection and identification of HLA-specific memory B cells which are poised to produce HLA-specific immunoglobulin injurious to transplanted grafts.

The research is being led by Dr. Frances Lund, Charles H. McCauley Professor and Chair Department of Microbiology, Dr. John Killian, resident in the Department of Surgery, and Dr. Rico Buchli, VP of Products and Services at PTS, and focuses on using PTS's newly created Class I and Class II biotinylated soluble HLA (sHLA) proteins to understand the breadth and specificity of HLA-reactive B cells in sensitized individuals. These proprietary HLA molecules can be utilized in standard flow cytometry workflows for easy processing and analysis that the parties hope will provide a new tool for clinicians and researchers to use when caring for transplant patients.

Almost all previous work on HLA sensitized individuals has relied upon assays that detect circulating anti-HLA antibodies. The goal is to determine the reactivities of HLA-reactive B cells in these sensitized patients and compare these reactivities to those that are present among circulating anti-HLA antibodies. Using panels of biotinylated HLA molecules in combination with various tetramerized fluorescent reagents allows the interrogation of the specific B cell receptors expressed by HLA-reactive B cells.

"Prevention of B cell activation and proliferation is crucial for the survival of a transplant patient. For patient monitoring, identifying the right approach to immune profiling at each stage of clinical development-including the later stages, when it is often considered impractical to include these approaches-may be critical for identifying predictors of rejection responses, or monitoring immunosuppression efficacy", said Dr. Buchli. "Flow cytometric analysis using our fluorescent tagged HLA products have the capabilities needed to meet the increased demands to detect, identify, and monitor HLA-specific memory B cells."

"Our research at the University of Alabama at Birmingham seeks to improve the success of organ transplants," said John Killian, Jr., M.D., a research resident in the UAB Department of Surgery. "One problem is that following pregnancy or transplant, patients form antibodies against non-self HLA molecules. These antibodies comprise a major barrier to transplantation, and they exacerbate gender and racial disparities for thousands of people who await a life-saving transplant. Thus, we want to understand the breadth and specificity of HLA-reactive memory B cells in sensitized women. Pure Protein's extensive selection of recombinant HLA molecules will be integral to our projects, allowing us to pair fluorescence-activated cell sorting of HLA-reactive B cells with subsequent analysis of recombinant-antibody specificities. An improved understanding of the phenotype and specificity of HLA-reactive B cells will offer new opportunities to diagnose and treat HLA sensitization."

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: www.puretransplant.com

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website, http://www.hlaprotein.com/, Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About the University of Alabama Birmingham

Known for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham, a part of the University of Alabama System, is an internationally renowned research university and academic medical center with over $600 million in research awards annually, as well as Alabama's largest employer, with some 23,000 employees, and has an annual economic impact exceeding $7 billion on the state. The pillars of UAB's mission include education, research, innovation and economic development, community engagement, and patient care. Learn more at https://www.uab.edu/.

Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with The University of Alabama at Birmingham (UAB), a leading institution in transplant research.

Related link: https://www.puretransplant.com/

Zeteo Biomedical Receives US Patent for Innovative Sublingual Delivery Device for Vaccines and Pharmaceuticals

AUSTIN, Texas /ScoopCloud/ -- Zeteo Biomedical, a privately held, biomedical device company, announced today it has been awarded a United States Patent for its "Oral Delivery Device and Methods" (US Patent 10238577). This latest patent expands the capabilities of Zeteo's ZEOx1™ Delivery Platform to systemically deliver drugs or biologics, into the body non-invasively via the sublingual route.

Sublingual delivery has emerged as a viable route of administration for vaccines and medications for pain, cardiovascular, allergy, seizure, sedation and emesis. The sublingual route avoids first pass metabolism and provides rapid systemic uptake into the body providing advantages over traditional oral medications.

Zeteo's latest innovations expand its ZEOx1 Hydra™ sublingual delivery device family that include configurations for mono-dose disposable and mono-dose reloadable dispensers for vaccines, drugs, biopharmaceuticals, biologics and botanical liquid formulations. "We see expanding demand for metered dose sublingual delivery devices that are easy to use, convenient to carry, deliver a precise dose and can be self-administered," said Timothy Sullivan, President of Zeteo Biomedical.

Zeteo's delivery device technology and product integration services enable pharmaceutical and biotech manufacturers to develop drug/device combination products that can extend or establish market exclusivity and competitive differentiation for new or existing drugs and biologics. The shift to developing value added, patient-centric products benefit the consumer through improved compliance and health outcomes while building brand value for the pharmaceutical or biotech manufacturer. Zeteo's delivery platforms and products are designed to meet the diverse demands of consumers and pharma manufacturers in globally competitive markets.

About Zeteo Biomedical LLC

Zeteo Biomedical™ is a biomedical device technology company based in Austin, Texas. Zeteo provides patient-centric delivery device technology and unit dose fill/finish packaging for pharmaceuticals, biopharmaceuticals, biologics and botanicals for intranasal, nose-to-brain, ophthalmic, sublingual, and animal care product applications.

For more information, please visit the Zeteo website at: https://www.zeteobiomed.com/

Media Contact
Cathy Diehl
Zeteo Biomedical LLC
+(1) 512-614-0144
zeteo@zeteobiomed.com

*LOGO link for media: https://www.send2press.com/300dpi/20-1117s2p-zeteo-biomedical-300dpi.jpg

Zeteo Biomedical, a privately held, biomedical device company, announced today it has been awarded a United States Patent for its "Oral Delivery Device and Methods" (US Patent 10238577). This latest patent expands the capabilities of Zeteo's ZEO Delivery Platform to systemically deliver drugs or biologics, into the body non-invasively via the sublingual route.

Related link: https://www.zeteobiomed.com/

Caisson Biotech, LLC and Heparinex, LLC Announce Positive Examination Report of European Patent and the Discovery of a New Class of Sugar Polymers

AUSTIN, Texas /ScoopCloud/ -- Caisson Biotech and parent company Heparinex are pleased to announce that they have received a positive examination report from the European Patent Office for a patent covering the chemoenzymatic production of heparosan utilized in the HEPtune® drug delivery platform. Once certified, the new patent family will increase patent coverage across Europe, adding to the U.S. holdings.

The HEPtune platform, which utilizes heparosan, a naturally occurring polysaccharide, has been validated as a novel half-life extension and drug delivery alternative to commonly used polyethylene glycol (PEG). Unlike PEG, heparosan is naturally found in humans, is completely biodegradable, and will not trigger anaphylactic shock or anti-drug antibodies. The HEPtune platform has been applied to numerous drug classes including biologics, and small molecules via nanocarriers, including liposomes.

In addition to positive news received by the EPO, Heparinex is excited to announce that it has created a new class of sugar polymers, sulfated hepbiuronic acid (sHBA) that mimic some, but not all, of the desirable activities of heparin, a drug employed to treat many diseases including the fight against severe COVID-19 and influenza. These novel patent-pending drug candidates can quell the initiation of inflammation, but do not inhibit blood coagulation, thus can be used to protect organs such as the lungs, heart, and kidneys that are often damaged by the body's own defenses during disease without the risk of bleeding. The sHBA should be a useful addition to the arsenal of drugs currently dispensed to treat hyper-inflammation spawned by infectious, cardiovascular, and auto-immune diseases.

Heparosan conjugation was developed by Presidential Professor Dr. Paul DeAngelis at the University of Oklahoma Health Sciences Center (OUHSC) and includes a robust U.S. and international patent portfolio. "Our goal is to decipher and harness the natural 'sugar codes' in the body in more selective, customized fashion to target diseases and reduce side effects. We are excited by the possibilities for better medicines", said DeAngelis. He was named as one of the most influential researchers in the world according to a study led by an investigator at Stanford University and published in PLOS Biology.

About Caisson Biotech, LLC

Caisson Biotech, LLC is a collaboration driven biotechnology company specializing in the development of heparosan polymers to improve therapeutic drug delivery and performance. Caisson's HEPtune® technology was invented by Chief Scientist and University of Oklahoma Professor Dr. Paul DeAngelis, a world renowned glycobiology and enzyme specialist. Visit: https://caissonbiotech.com/.

Caisson Biotech is a subsidiary of Heparinex, LLC.

About Heparinex, LLC

Heparinex, LLC is a biopharmaceutical company focused on the novel recombinant synthesis of sugar-based compounds for markets including anticoagulation, inflammation, and cancer treatment. Dr. Paul DeAngelis originally discovered and patented Heparinex's core technology platforms of proprietary carbohydrate production. Visit: https://heparinex.com/.

Heparinex and Caisson are funded and managed by Emergent Technologies, Inc. an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: http://www.emergenttechnologies.com/

Caisson Biotech and parent company Heparinex are pleased to announce that they have received a positive examination report from the European Patent Office for a patent covering the chemoenzymatic production of heparosan utilized in the HEPtune® drug delivery platform. Once certified, the new patent family will increase patent coverage across Europe, adding to the U.S. holdings.

Related link: https://caissonbiotech.com/

Rescindo Therapeutics’ RSC-57 Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Kabuki Syndrome

CARY, N.C. /ScoopCloud/ -- Rescindo Therapeutics Inc., a drug discovery company dedicated to the development of new treatments for rare genetic disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation and Rare Pediatric Disease Designation for the Company's lead drug RSC-57, for the treatment of patients with Kabuki Syndrome.

"We are honored to receive these very important designations for our lead drug for Kabuki Syndrome. The decision validated the urgency and need for treatment of this devastating disease for which there are no FDA-approved therapies," said Dr. Athanasios (Thanos) Maroglou, co-founder, President and CEO of Rescindo. "With RSC-57 being a repurposed drug with a large established safety profile, we hope to proceed with clinical trials rapidly after the completion of our pre-IND package and guidance from the FDA."

Orphan Drug Designation is granted by the FDA to drugs or biologics intended to treat a rare disease or condition, defined as one that affects fewer than 200,000 people in the United States. Programs with Orphan Drug status receive partial tax credit for clinical trial expenditures, waived user fees and eligibility for seven years of marketing exclusivity.

Rare Pediatric Disease Designation is granted by the FDA in the case of serious or life-threatening diseases affecting fewer than 200,000 people in the United States, primarily those 18 years of age and younger. The sponsor of a drug with Rare Pediatric Disease Designation may, upon marketing approval, qualify for receipt of a priority review voucher applicable to a subsequent marketing application, which voucher is fully transferable.

About Kabuki Syndrome

Kabuki Syndrome is a rare developmental disorder characterized by intellectual disability, muscle hypotonia, distinctive facial features, short stature, immune deficiency and malformations of the cardiac, renal, gastrointestinal, and/or skeletal systems. Typically diagnosed during early childhood, it is possible to identify KS as early as infancy based on characteristic facial features and associated organ malformations.

The global prevalence of KS is estimated at 1:32,000 births, although its incidence is likely underestimated, as judged by the acceleration of new cases now that genome sequencing is becoming more broadly available. At present, KS has no cure.

About Rescindo Therapeutics Inc.

Rescindo Therapeutics is drug discovery and development company focused on rare genetic diseases to improve peoples' lives.

Rescindo Therapeutics Inc. was founded in 2015 by Dr. Athanasios Maroglou and Dr. Nicholas Katsanis with an objective to discover and develop new drugs for children with rare genetic diseases. Using a novel approach that combines genetics, molecular biology, and high throughput use of model organisms, we accelerate the discovery of new therapies. Together with our academic, private sector partners, and patient advocacy groups, we are working toward bringing new treatments for life-threatening disorders.

Learn more at: https://www.rescindotherapeutics.com/

*LOGO link for media: https://www.Send2Press.com/300dpi/21-0214s2p-rescindo-300dpi.jpg

Rescindo Therapeutics Inc., a drug discovery company dedicated to the development of new treatments for rare genetic disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation and Rare Pediatric Disease Designation for the Company's lead drug RSC-57, for the treatment of patients with Kabuki Syndrome.

Related link: https://www.rescindotherapeutics.com/

Kalyagen Announces Launch of ‘Stem the Tide of Time’ Campaign Featuring NBA Hall of Fame Finalist Marques Johnson

AUSTIN, Texas /ScoopCloud/ -- Kalyagen™ is pleased to announce the launch of its "Stem the Tide of Time" social media campaign featuring former UCLA Bruin and Milwaukee Buck All-Star Marques Johnson to promote STEMREGEN®, a natural stem cell enhancer documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).

"The link between a lower number of circulating stem cells and the development of age-related problems has been well documented, and increasing the number of circulating stem cells has also been well documented to enhance tissue repair and improve the course of many age-related conditions," said Christian Drapeau, CEO and Chief Scientist of Kalyagen™. "Stemregen can indeed help to stem the tide of time, and the campaign asks the question "what does Stem the Tide of Time mean to you?"

The campaign, designed to increase awareness of STEMREGEN®, is launching to coincide with Marques Johnson's annual birthday dunk.

"Eleven years and 27,000 minutes of running and jumping up and down NBA floors has taken its toll on my body," said Marques Johnson. "'Stem the Tide of Time' for me means that I can slow or stop the onset of stiffness and soreness so I can participate in the lives of my children and grandchildren in a meaningful way. And with my 65th birthday upon us, we'll see if I've stemmed the tide and can still dunk!"

STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to support ESCM and increase the number of circulating stem cells, thereby supporting the natural ability of the body to repair and stay healthy. Ingredients in STEMREGEN® have been investigated in more than eight studies for their effect on stem cell function, of which five were randomized, double- blind, placebo-controlled human clinical trials. STEMREGEN® has wide application in antiaging and overall health maintenance.

About Kalyagen

Kalyagen™ was founded by Christian Drapeau, author of the bestseller Cracking the Stem Cell Code. Kalyagen is a leader in the research and development of natural products aimed at supporting stem cell function of the body. Stem cells constitute the natural repair system of the body, and stem cell enhancers have been documented to strongly contribute to improving health and quality of life. STEMREGEN® is the first stem cell enhancer product developed by Kalyagen™. STEMREGEN® is a unique blend of proprietary plant-based extracts documented to support Endogenous Stem Cell Mobilization and provide other health benefits.

For more information, please visit our Website: https://www.kalyagen.com/.

About Marques Johnson

Marques Johnson is a basketball analyst for the Milwaukee Bucks on Fox Sports Net. He played college basketball for the UCLA Bruins, won a national championship in 1975 and was the College Player of the Year as a senior. A five-time All-Star, he played seven seasons with Milwaukee before finishing his NBA career with the Los Angeles Clippers and the Golden State Warriors. He is currently a finalist for the NBA Hall of Fame and can still dunk at the age of 65.

*VIDEO (YouTube): https://youtu.be/aGJibMXwmuw

Media Contact:
Biomics, LLC (dba Kalyagen™)
Herbert Dogan, Chief Marketing Officer
(310-433-8072)
hgd@kalyagen.com

Social media: @kalyagen #stemthetideoftime #stemthetide

Disclaimer: None of the statements contained in this press release have been evaluated by the Food and Drug Administration. The products and information in the release are not intended to diagnose, treat, cure or prevent any disease.

Kalyagen is pleased to announce the launch of its "Stem the Tide of Time" social media campaign featuring former UCLA Bruin and Milwaukee Buck All-Star Marques Johnson to promote STEMREGEN;, a natural stem cell enhancer documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).

Related link: https://www.kalyagen.com/

Kalyagen™ Announces Launch of Clinical Trial to Evaluate STEMREGEN® and Stem Cells for Advanced Heart Failure Patients

AUSTIN, Texas /ScoopCloud/ -- Kalyagen™, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the "Spanish Society of Regenerative Medicine and Cell Therapy"), is pleased to announce the launch of a multicenter clinical trial, "The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart Failure," to evaluate the use of stem cell therapies in patients suffering from heart failure. STEMREGEN® is a natural stem cell enhancer documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).

"The link between a lower number of circulating stem cells and the development of age-related diseases has been well studied with numerous degenerative conditions, including diabetes, cardiovascular diseases, atherosclerosis, Alzheimer's disease, rheumatoid arthritis, pulmonary diseases, erectile dysfunction, and kidney disease," said Christian Drapeau, CEO and Chief Scientist of Kalyagen™. "From a therapeutic standpoint, increasing the number of circulating stem cells has been documented to enhance tissue repair or improve the course of disease formation in cases of acute myocardial infarction and many other degenerative conditions."

The trial, whose first phase is expected to be completed in the fall of 2021, aims to evaluate the effect of ESCM in cases of heart failure. Forty-five patients who suffered from acute myocardial infarction will be randomly distributed into three groups: i) STEMREGEN® alone, ii) injection of stem cells (SVF), and iii) combined consumption of STEMREGEN® and stem cell injection. The dietary supplement will be provided at a dose of 2 capsules three times a day for 3 to 6 months. Study participants will be evaluated after 1, 3, 6 and 12 months, at which times their NYHA functional classification and echocardiographic parameters will be assessed. The first phase will begin with 15 patients.

"We have had a great deal of success treating patients suffering from advanced heart failure with stem cells," said Miguel Garber, MD, Vice Chairman of the Spanish Society of Regenerative Medicine and Cell Therapy. "Unfortunately, traditional stem cell therapy utilizing Stroma Vascular Fraction is not widely available. We are hopeful that treating patients with STEMREGEN, a much more cost-effective widely-available therapy, can show similar beneficial health outcomes, and that it can further improve patient outcomes when combined with SVF therapy."

STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to support ESCM. Ingredients in STEMREGEN® have been investigated in more than eight studies for their effect on stem cell function, of which five were randomized, double-blind, placebo-controlled human clinical trials. STEMREGEN® has wide application in antiaging and overall health maintenance.

More information about the clinical trial can be found at https://clinicaltrials.gov/ct2/show/NCT04515537.

About Kalyagen

Kalyagen™ was founded by Christian Drapeau, author of the bestseller Cracking the Stem Cell Code. Kalyagen is a leader in the research and development of natural products aimed at supporting stem cell function of the body. Stem cells constitute the natural repair system of the body, and stem cell enhancers have been documented to strongly contribute to improving health and quality of life. STEMREGEN® is the first stem cell enhancer product developed by Kalyagen™. STEMREGEN® is a unique blend of proprietary plant-based extracts documented to support Endogenous Stem Cell Mobilization and provide other health benefits. For more information, please visit our Website: https://www.kalyagen.com/

About Miguel Garber

Miguel Garber has over 32 years of experience in internal medicine and cardiology, with expertise in regenerative medicine, training and education, and research. He has more than 14 years working with Stem Cells, Therapeutics Department of American Medical Information Group and Clinica Quirurgica Quantum. Medical Director of Regenerative Medicine Madrid, Professor of Master in Regenerative Medicine and Scholarly Journals Editor. Vice-chairman - Sociedad Espanola de Medicina Regenerativa y Terapia Celular.

Media Contact:
Biomics, LLC (dba Kalyagen™)
Herbert Dogan
Chief Marketing Officer
(310-433-8072)
hgd@kalyagen.com

Social media: @kalyagen #stemthetideoftime #stemthetide

###
Disclaimer: None of the statements contained in this press release have been evaluated by the Food and Drug Administration. The products and information in the release are not intended to diagnose, treat, cure or prevent any disease.

Kalyagen™, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the "Spanish Society of Regenerative Medicine and Cell Therapy"), is pleased to announce the launch of a multicenter clinical trial, "The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart Failure," to evaluate the use of stem cell therapies in patients suffering from heart failure.

Related link: https://www.kalyagen.com/

EPIC Insurance Brokers & Consultants Acquires Pharmaceutical Strategies Group

SAN FRANCISCO, Calif. /ScoopCloud/ -- EPIC Holdings, Inc. (EPIC) announced today that it has agreed to acquire Pharmaceutical Strategies Group (PSG). The move incorporates the expertise and resources of the nation's largest independent pharmacy benefit consulting firm into EPIC's Employee Benefits Consulting practice.

As a strategic partner to self-insured employers, health plans and health systems, PSG is an experienced navigator of the complex drug pricing market, and generates more than $4.8 billion in drug cost savings for clients each year.

"The opportunity to continue the next phase of our journey with EPIC is exciting," said Dave Borden, PSG Founder. "For more than 25 years, our dedicated clinicians and consultants have relentlessly advocated for clients, harnessing innovation to deliver the highest standard of pharmacy benefits consulting and technology."

Commenting on the announcement, Scott Schanen, President, EPIC National Employer Consulting, said, "Joining forces with PSG accelerates our ability to establish a new normal amid the dynamic landscape of employee engagement, health and economics. Long regarded as the industry leader in drug cost management, PSG's partnership with EPIC creates value for clients through independent, objective and sustainable solutions and strategies."

Steve Denton, EPIC CEO, added, "The cultural fit between PSG and EPIC has been apparent at every turn. We are collaborating to bring the combined expertise and breadth of service offerings to our clients and look forward to a positive 2021."

Michael Lonergan will continue to serve as PSG President and will lead the charge to develop innovative drug management solutions for U.S. plan sponsors. PSG will operate as "Pharmaceutical Strategies Group - an EPIC company."

About EPIC Brokers & Consultants

EPIC Insurance Brokers & Consultants has more than 2,600 team members operating from more than 80 offices across the U.S., providing Property and Casualty, Employee Benefits, Specialty Programs, and Private Client solutions to EPIC clients. For more information on EPIC, visit: https://epicbrokers.com/.

About Pharmaceutical Strategies Group

PSG is the leading pharmacy intelligence and technology company solving one of healthcare's biggest challenges - rising drug costs. It provides innovative drug management solutions to many of America's largest self-funded employers and health plans, who rely on trusted advisors to improve their financial performance.

EPIC Holdings, Inc. (EPIC) announced today that it has agreed to acquire Pharmaceutical Strategies Group (PSG). The move incorporates the expertise and resources of the nation's largest independent pharmacy benefit consulting firm into EPIC's Employee Benefits Consulting practice.

Related link: https://www.epicbrokers.com/

Zeteo Biomedical to Collaborate with Iowa State University Nanovaccine Institute to Study a COVID 19 Vaccine Under Fast Track CARES Act Funded Program

AUSTIN, Texas /ScoopCloud/ -- Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2(TM) Delivery Platform, along with technical services to support the evaluation of a room temperature stable SARS-CoV-2 vaccine under development by ISU's Nanovaccine Institute.

Zeteo ZEO(TM) Delivery Platforms provide nasal delivery device configurations to support vaccine development during early stage pre-clinical animal studies, human clinical trials and are commercially scalable to fill/finish and deliver millions of doses per day for a global supply of nasal vaccines or medical countermeasures in the event of a pandemic crisis.

ISU's vaccine is expected to provide long-term protection against SARS-CoV-2, the novel coronavirus that causes COVID-19, and is intended to address some of the limitations of the vaccines currently in development by targeting room temperature storage and single dose nasal self-administration as key capabilities.

"Our approach leverages the strengths of ISU's nanovaccine platform and Zeteo's ZEOx2 nasal delivery platform and brings together a world-class team of scientists and engineers providing expertise for vaccine formulation, pre-clinical and clinical evaluations, fill/fit/finish packaging, nasal delivery devices and manufacturing scale-up," said Dr. Balaji Narasimhan, Director of the Nanovaccine Institute at Iowa State University.

Zeteo's ZEOx2 Delivery Platform includes nasal delivery devices to support powder and reconstituted powder to liquid vaccine formulations that can be either caregiver- or self-administered.

Timothy Sullivan, President of Zeteo Biomedical, said "We are honored to have been selected by the ISU Nanovaccine Institute to provide our technology and expertise in nasal drug delivery and packaging to support this critically important project to address the global health devastation caused by COVID 19."

Additional collaboration partners involved in the project include the Southwest Research Institute (San Antonio, TX), Skroot Laboratory, Inc. (Ames, IA), and the University of Iowa (Iowa City, IA). This is a fast track project and is expected to be completed by the end of the year.

About Zeteo Biomedical LLC

Zeteo Biomedical(TM) is a biomedical device technology company based in Austin, Texas. Zeteo provides patient-centric delivery device technology and unit dose fill/finish packaging for pharmaceuticals, biopharmaceuticals, biologics and botanicals for intranasal, nose-to-brain, ophthalmic, sublingual, and animal care product applications. For more information please visit the Zeteo website at: https://www.zeteobiomed.com/.

Media Contact
Cathy Diehl
Zeteo Biomedical LLC
+(1) 512-614-0144
zeteo@zeteobiomed.com

*LOGO link for media: https://www.send2press.com/300dpi/20-1117s2p-zeteo-biomedical-300dpi.jpg

Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2 Delivery Platform.

Related link: https://www.zeteobiomed.com/

Avila Herbals Announces Manufacturing and Research and Development Agreements with Phoenix Biotechnology

CHRISTIANSBURG, Va. /ScoopCloud/ -- Avila Herbals, a company specializing in novel botanical extraction techniques for both dietary supplements and pharmaceuticals, announced today that it has signed an exclusive global manufacturing agreement and a research and development agreement with Phoenix Biotechnology (San Antonio, TX), a company that has been exploring the health-related benefits of novel extracts of Nerium oleander for the past 25 years.

Avila Herbals began product development activities in the spring of 2020 and optimized several different proprietary extraction techniques. The company developed the formulation and the products and has scaled manufacturing in anticipation for a launch of several different products. Each product contains a unique extract from the Nerium oleander plant. Phoenix has filed several patent applications based on this work related to SARS-CoV-2 infection and the COVID-19 pandemic.

"We look forward to working with Phoenix Biotechnology. We are committed to developing and manufacturing several new oleander-based products with Phoenix," commented Dr. Richard Obiso, co-owner and CSO of Avila Herbals. "We are thrilled to be able to apply our research and manufacturing expertise to the development of these products."

The agreements support continued manufacturing so that the product can be made available in the United States and internationally. The agreements also cover the development and manufacture of a pharmaceutical, if clinical trials are approved by the US Food and Drug Administration (FDA); although the specific terms of the agreements were not disclosed.

Since Q2 CY2020, Avila Herbals and its partners have invested over $4.5 million dollars into the development and commercialization of these products in the New River Valley of Virginia. Avila has created more than 50 full-time jobs in just a few months to support the development and manufacturing of these products.

"Avila Herbals contributes to the economy of the New River Valley. The company's research and development of the potential health benefits of the extract of Nerium oleander is impressive, and we thank Avila and Phoenix for their commitment to the region and to the Commonwealth," said US Congressman Morgan Griffith.

According to Theresa Obiso, co-owner and CEO of Avila Herbals, "When we began our collaborations, we immediately scaled to meet this need; doing so here in Christiansburg allows us to leverage strong local relationships and build a world-class team."

"Avila Herbals' expansion is a significant win for our region's future and our growing economy," said Virginia Delegate Nick Rush. "Avila is a technology leader that exemplifies the New River Valley's entrepreneurial spirit," Delegate Rush continued. "I wish Avila Herbals much success as it moves forward to becoming one of SWVA's newest technology success stories."

About Avila Herbals

Avila Herbals has created a sustainable agriculture program in the New River Valley of Virginia that focuses on the production of the highest quality botanicals for use in nutraceuticals and botanical pharmaceuticals. The team uses supercritical carbon dioxide extraction as well as novel cryo-ethanol methods, and has launched several botanical preparations. Our passion is sustainable agriculture, organic techniques, and biodynamic farming practices. At Avila Herbals, we work hard to exceed regulatory standards, because we believe in sustainability and great quality. All of our products are manufactured in our GMP facilities.

About Phoenix Biotechnology

Phoenix Biotechnology, Inc. is a San Antonio, Texas-based biotechnology company that was incorporated in Texas in 2003 to develop promising agents from Nerium oleander with minimal or no side effects for targeted therapy in three areas: malignant tumor growth (an extract of Nerium oleander has been found to bind to discrete cellular targets in solid tumors in vitro and in vivo), neurological disorders (ischemic stroke, Alzheimer's disease, and Huntington's disease), and viral diseases. To date, Phoenix has identified potent antiviral activity against Ebola and Marburg viruses, cytomegalovirus, herpes simplex viruses, HIV and HTLV-1, and SARS-CoV-2.

For more information about Avila Herbals, please contact Avila Herbals at info@avilaherbals.com (preferred) or 1-540-808-2314.

On the web: https://avilaherbals.com/

*LOGO link for media: https://www.Send2Press.com/300dpi/20-1028x2p-avila-herbals-300dpi.jpg

Avila Herbals, a company specializing in novel botanical extraction techniques for both dietary supplements and pharmaceuticals, announced today that it has signed an exclusive global manufacturing agreement and a research and development agreement with Phoenix Biotechnology.

Related link: https://avilaherbals.com/

NED Biosystems Announces Leading Infectious Disease Research Scientist Michael Mansour, MD, PhD To Serve as Medical Advisor

CAMBRIDGE, Mass. /ScoopCloud/ -- NED Biosystems, an innovative clinical-stage biotech company developing therapies for cancer and the novel coronavirus, is pleased to announce that Michael Mansour, MD, PhD, will serve as the Company's Medical Advisor of Infectious Disease. Dr. Mansour brings a wealth of expertise in infectious disease research where he leads an independent laboratory at the Massachusetts General Hospital (MGH). He is a leading authority guiding investigative studies on COVID-19 treatments and biomarkers which includes serving as Principal Investigator for Phase 3 COVID-19 studies.

As Medical Advisor, Dr. Mansour will direct NED's clinical trial initiative for NED-260 to establish the treatment's safety and efficacy for COVID-19 patients. NED-260 is a rationally designed, combination treatment that has the potential to address COVID-19 viral replication and entry based on its multiple mechanisms of action. Through its multifaceted approach to address major processes integral to COVID-19's progression and how it infects the cell, NED-260 may fulfill a critically important niche in the treatment and prevention of mild-to-moderate illness in the majority of people who are at risk for COVID-19 infection. NED is planning to conduct a Phase 2, randomized, placebo-controlled study of NED-260 in mild-to-moderate COVID-19 patients.*

"This study offers a chance to look at an oral treatment for COVID-19," said Dr. Mansour. "Taken directly after diagnosis, the combination is aimed at interrupting disease progression - and potentially speeding up a patient's recovery time. The trial will also explore the use of NED-260 as a potential prophylaxis, to prevent infection."

"The contribution of Dr. Mansour's expertise and considerable insight will be invaluable as we establish the safety and efficacy of NED-260 as a COVID-19 treatment," stated Rebecca Lambert, Founder and Executive Chair of NED Biosystems. "We are eager to commence the NED-260 clinical trials with Dr. Mansour's seasoned guidance. The time is now to develop an early treatment solution and preventative of infection."

"Dr. Mansour is an outstanding addition to our team of accomplished medical advisors at NED Biosystems," stated Dr. Geoffrey Ling, Office of the CEO, Scientific Advisory Board, Board of Directors, NED Biosystems and advisor to the U.S. Government's COVID-19 Task Force. "His prominence in the field of infectious disease research and deep expertise will help propel our efforts to bring our uniquely comprehensive treatments to the broader patient community. We are delighted to welcome him to the team."

Dr. Mansour leads a team of medical research scientists at the Mansour Laboratory that focuses on developing novel cellular diagnostics and therapies for invasive fungal infections. He is also a practicing physician specialized in infectious disease at MGH. Dr. Mansour obtained an MD and PhD from Boston University and completed his residency and served as a fellow at the MGH.

About NED Biosystems(TM)

Based in Cambridge, Massachusetts, NED Biosystems is a clinical-stage biotech company developing innovative treatments to provide multifaceted approaches to affect multiple key disease processes. Beginning with a focus on patients and their families, NED seeks to dramatically improve patient outcomes with combination treatments comprised of agents with well-established safety and tolerability profiles. NED's treatment approach is to afford patients high quality of life. Due to ease of oral dosing and cost-effectiveness of the treatments, the company aims to provide revolutionary, efficacious treatment solutions to patients not only in the U.S. and other developed nations, but also in economically challenged regions globally.

For more information, visit https://nedbiosystems.com/.

For additional information regarding this press release, please contact Creative Director, Brett Macias at bmacias@nedbiosystems.com.

*NED-260 is pending approval by the FDA post clinical trials.

PHOTO link for media: https://www.Send2Press.com/300dpi/20-1006s2p-ned-michael-mansour-300dpi.jpg

Caption: Michael Mansour, MD, PhD, NED Biosystems' New Medical Advisor of Infectious Disease.

NED Biosystems, an innovative clinical-stage biotech company developing therapies for cancer and the novel coronavirus, is pleased to announce that Michael Mansour, MD, PhD, will serve as the Company's Medical Advisor of Infectious Disease.

Related link: https://nedbiosystems.com/

US Pharmaceutical Corporation® Introduces Patented Hylafem® pH Vaginal Suppositories Consisting of Boric Acid in a Probiotic Blend

DECATUR, Ga. /ScoopCloud/ -- US Pharmaceutical Corporation(R), the probiotic and nutritional supplement company, launches Hylafem(R) pH vaginal suppositories, a unique, patented, homeopathic suppository product which efficaciously tackles recurring women's vaginal health issues.

Introducing Hylafem(R) pH, a patented, over-the-counter, probiotic-based vaginal suppository with an easy applicator. Hylafem(R) pH effectively addresses symptoms of bacterial vaginosis (BV), urinary tract infections, vaginal bacterial and yeast infections and post-menopausal dryness, with minimal to no side effects.

"Developing new and innovative products is a passion of mine. My focus is on delivering effective alternatives to traditional pharmaceutical therapies. I am inspired by the ever-evolving benefits of microbes in and on our bodies that are being revealed," said Allison Krebs, CEO, US Pharmaceutical Corporation.

Hylafem(R) pH relies on the power of probiotics to restore the vaginal microbiome to a state of equilibrium. One fast-dissolving probiotic suppository capsule, adhering to the mucosal membrane, lowers pH from 7.0 to 4.5 within 5 minutes after administration. Most over-the-counter oral probiotics may not even reach the vaginal canal, but Hylafem(R) pH directly delivers the probiotics necessary to balance and maintain a healthy vaginal microbiome, which may help stimulate the immune response during vaginal infections.

Easy to self-administer, with none of the potentially dangerous side effects associated with clindamycin, and none of the messiness of metronidazole gels, Hylafem(R) pH is affordable, manufactured and produced in FDA-registered facilities, and provides effective relief, in many instances, with one dose in one day.

NDC 52747-0255-03
U.S. Patent No: 6,797,266 and 10,258,567

OUR EFFECTIVE INGREDIENTS

* Probiotics: Hylafem(R) pH releases 200 billion CFUs of Lactobacillus casei (KE-99) and 100 billion CFUs of Lactobacillus gasseri. Lactobacillus casei produces lactic acid that helps provide a healthy vaginal environment; Lactobacillus gasseri produces bacteriocin, a protein that helps fight bad bacteria.
* Homeopathics: Boricum Acidum 3XHPUS is a homeopathic dilution that combats yeast infections.
* Antioxidants: Vitamins E and C fight free radicals.
* Plant-based capsule: The capsule is made of pullulan, a plant-based material that stabilizes the organism for maximum effectiveness and extended shelf-life.

WHAT HYLAFEM(R) pH DOES

• Treats vaginal bacterial and yeast infections
Bacterial Vaginosis (BV) is one of the most common infections in women of reproductive age. BV occurs when there is an imbalance of good vs. harmful bacteria in the vaginal microbiome.

• Rebalances vaginal pH and restores vaginal health
A rise in pH can increase the likelihood of infection. One vaginal suppository repopulates the vagina with lactobacilli, the predominant bacteria in healthy women, creating an unfavorable environment for the growth of bacteria including pathogens.

• Helps relieve burning, itching, irritation, inflammation and dryness, inside and out

• Helps reduce odors due to vaginal infection

* Additional applications Also recommended for prevention and maintenance of post-menopausal, post-childbirth, post-surgical, chemotherapy, diabetes-related conditions. In the U.S., 32 million post-menopausal women seek relief from the chronic pain associated with vaginal dryness, cracking and itching.

• Reduces recurrence Clinical management of BV has made little progress in the past two decades. The first-line antibiotic therapy showed 70 to 80 percent curative rates after four weeks of treatment, however, high rates of recurrence occurred within 12 months, reaching 40 to 50 percent.

SUPERIOR BENEFITS

Many products are designed to provide relief for the symptoms associated with BV, UTI and vaginal dryness. But clinical studies show that, unlike Hylafem(R) pH, traditional treatments do not directly address the main causal imbalance of the lactobacillus-dominated (healthy) vaginal flora in the vaginal microbiome and therefore recurrence is frequent.

Hylafem(R) pH is:

* Highly effective and offers sustained relief About 21 million American women under the age of 49 suffer from an outbreak of BV at least once per year. According to the Centers for Disease Control (CDC), most have a recurrence within 6 to 12 months, and enter a cycle of antibiotic use.

* Targeted with an improved side-effect profile: Non-hormonal, reduced cancer risk, blood clot risk.

* Non-prescription: Available over-the-counter

* In powder form: Reduces messiness post-application

* Simple and effective: Contains only six ingredients, delivered in a plant-based capsule.

Hylafem(R) pH can be purchased at https://bit.ly/hylafemph for $29.95 MSRP.

About US Pharmaceutical Corporation

US Pharmaceutical Corporation(R) is a family-operated pharmaceutical company based in Atlanta, Georgia, with a specialty in patented prescription nutritional supplements and probiotics. We are proud to serve our patients and customers across the USA, under the same ownership, since 1954. Our team has a lifelong commitment to health and well-being, with probiotics being a consistent part of their daily regimen.

When we develop new medications and devices, the first question we ask ourselves is, "What would we like if we were the patient?" That's how we developed our slogan "Products designed with the patient in mind." US Pharmaceutical Corporation(R) provides product literature, free samples and product vouchers to health-care providers.

Learn more at: https://www.uspco.com/product_literature.aspx?pid=436

Media Only Contact:
Nancy Wilson
Of US Pharmaceutical Corporation
+1-770-987-4745 EXT. 176
n.wilson@uspco.com
web: https://uspco.com/

*LOGO link for media: http://www.Send2Press.com/300dpi/20-0817s2p-UDPHARM-300dpi.jpg

Disclaimer: These statements have not been evaluated by the FDA. This product is not intended to cure, diagnose, or prevent any disease.

US Pharmaceutical Corporation, the probiotic and nutritional supplement company, launches Hylafem pH vaginal suppositories, a unique, patented, homeopathic suppository product which efficaciously tackles recurring women's vaginal health issues.

Related link: https://www.uspco.com/

Thar Process Expands into India to Focus on Pharmaceutical Purification Market

PITTSBURGH, Pa. /ScoopCloud/ -- Thar Process, Inc - an American manufacturer of high-tech supercritical CO2 extraction and purification equipment - is proud to announce the signing of a new exclusive distribution deal with YMC India (a subsidiary of YMC Co. Ltd., JAPAN). YMC India will now provide Thar's supercritical extraction and chromatographic systems and expertise to the greater India region.

Through this new partnership, Thar Process is furthering their overall mission to design, develop and distribute top-tier quality equipment for the food and pharmaceutical communities, with a dedication and responsibility as an industry leader to help push the emerging market forward and set a higher standard - what Thar calls "Sustainable + Trust."

YMC India proudly leads India in sales of bulk chromatography media and industrial scale chromatography equipment to the world's largest pharmaceutical manufacturing market. YMC Co. Ltd., JAPAN is internationally reputed for its strong background in stationary phases / chromatographic media for the pharmaceutical industry while also selling preparative to process-scale normal and reverse phase liquid chromatography (LC) equipment.

While YMC India will continue to sell those systems, the Thar Process series of SuperFast CO2 Extraction(tm) and Isolator SFC(tm) systems expands their reach into a new markets including the extraction Ayurvedic natural medicines, essential oils, flavors, fragrances; the purification of hemp and palm oil plus chiral separations and impurity remediation for pharmaceuticals.

The partnership between Thar Process and YMC India brings together knowledgeable and experienced engineering with the highest level of pharmaceutical industry-specific expertise to further advance the evolving technology and provide innovative products to the South Asian market.

About Thar Process

Thar is committed to bringing innovation to the industry and providing a reliable source for all natural product oil extraction needs, providing clients the training and education to become a premium FDA registered, USDA Organic processor - like Thar in its Pittsburgh HQ.

Please visit https://tharprocess.com/.

About YMC India

YMC India Pvt. Ltd is a subsidiary of YMC Co. Ltd., JAPAN. with its head office at New Delhi and sales network PAN India. YMC India hold its strong presence throughout the pharmaceutical industry with its diversified product portfolio having column chemistry, Bulk Media, Flash chromatography, large scale HPLC purification systems and large-scale DAC columns and other lab consumables coupled with a highly qualified & dedicated workforce of 50 people. YMC India owns a Custom Purification LAB at Hyderabad where all the application support to our end user is provided.

Please Visit https://ymcindia.com/.

Thar Process, Inc - an American manufacturer of high-tech supercritical CO2 extraction and purification equipment - is proud to announce the signing of a new exclusive distribution deal with YMC India (a subsidiary of YMC Co. Ltd., JAPAN).

Related link: http://tharprocess.com/

A Novel Treatment Approach to Silent Hypoxia in COVID-19 Patients

PARK CITY, Utah /ScoopCloud/ -- Silent Hypoxia is a frequent disabling and sometimes fatal complication in COVID-19 disease. To prevent SARS-CoV-2 coronavirus-induced damage to patients' lungs and Silent Hypoxia in patients, Aristea Translational Medicine Corp. has initiated development of PhenT, a drug with novel cellular protective properties.

As a leading cause of death in infected patients, SARS-CoV-2 coronavirus-induced respiratory system damage in Covid-2 disease presents a significant and growing cause for concern worldwide. Based on the ability of PhenT to protect brain cells in neurological disorders, Aristea expects PhenT to shield lung cells and prevent COVID-19 patient's progressing into Silent Hypoxia, In Silent hypoxia insufficient oxygen reaches the blood as it passes through the lungs. It is a complication in COVID-19 that may require oxygen administration, intubation to allow machine-controlled breathing for patients associated with poor outcomes, and lead to death.

COVID-19

Coronavirus-induced respiratory system damage occurs even in persons who are not obviously symptomatic or asymptomatic but infected with SARS-CoV-2 coronavirus.

In healthy persons, lipids and proteins protect the alveoli - tiny air sacs in the lungs. These lipoproteins protect the alveoli from collapsing and failing to inflate during inhalation. In lungs battling COVID-19, viral induced damage removes the lipid and protein protection of alveoli Alveolar cells collapse and no longer adequately oxygenate the blood of the patient. Patients with this complication rapidly further damage lung tissue by overstretching with inspiration or ventilation. This risk requires an intervention to prevent progression in Silent Hypoxia.

PhenT

PhenT has been shown to block cell dysfunction and death in cultured cells and in five animal models of head trauma, stroke, Alzheimer's disease and nerve gas toxicity. For COVID-19, this protection could extend alveolar cellular function, maintaining their lipoprotein production in alveoli. This action raises the functioning capacity of the lung to maintain oxygen saturation of blood. With this protection of alveoli, lung structures are saved from overstretching and succumbing to the damage observed in progressive SARS-Cov-2 virus infections.

About Aristea Translational Medicine Corp.

Aristea Translational Medicine Corp. is a Utah-based small business. Since its incorporation in 2000, with others located at the National Institute on Aging, NIH, and at U.S., Canadian, and U.K. universities, Aristea has investigated the sources of failures in therapeutic drug developments and methods for overcoming unnecessary failures.

Beginning in 2010, with investigators at the National Institute on Aging, Aristea turned its expertise in drug development to clinical pharmacological research that has led to the use of PhenT and its proposed applications for preventing cell dysfunction and death in COVID-19 disease.

With the support of Aristea and a $4 million, five-year grant from the National Institute of Aging, collaborators at the University of Southern California, U.S. and at the University of Exeter, U.K. are carrying out clinical trials testing PhenT as a treatment to arrest progression in Alzheimer's disease. Aristea has PhenT patents and patents pending and emphasizes that this is an opportunity announced only to facilitate empirical evaluation.

Learn more: https://aristeatm.com/

Aristea Translational Medicine Corp., 3435 Cedar Drive, Park City UT 84098

Silent Hypoxia is a frequent disabling and sometimes fatal complication in COVID-19 disease. To prevent SARS-CoV-2 coronavirus-induced damage to patients' lungs and Silent Hypoxia in patients, Aristea Translational Medicine Corp. has initiated development of PhenT, a drug with novel cellular protective properties.

Related link: https://aristeatm.com/

ROKiT Pharma’s Preclinical Studies Showing Tremendous Promise for Naturally Derived Cancer Drug, ROK-001 – Moving Towards The Initiation Of Phase 1b/2 Clinical Trial

LOS ANGELES, Calif. /ScoopCloud/ -- ROKiT Pharma, Inc., a public-benefit corporation dedicated to putting patients first, announced today it is rapidly progressing through final preclinical studies and moving forward with preparation for the initiation of a Phase 1b/2 clinical trial of ROK-001, a potentially low toxicity cancer drug derived from natural ingredients.

During the Phase 1b trial, ROKiT Pharma's goal will be to determine the safety and tolerability of the drug in humans, as well as understand the pharmacokinetic and pharmacodynamic properties. If ROK-001 gains IND approval, ROKiT Pharma would like to open its first clinical trial during the summer of 2020. Discussions are currently underway with two prominent hospitals for this trial.

"The University of Sydney found the naturally occurring compounds on Kangaroo Island, we then completed our multiyear process of developing the synthetic processes and patenting the compound and related analogs," said Dean Becker, chairman and CEO of ROKiT Pharma and globally recognized leader in IP strategy. "Our plan is to produce large quantities of the drug - enough for universal need - so that we can really help people combat this disease through more natural sources. Unleashing nature is our goal - we want to provide these potentially life prolonging drugs, in oral pill form, at a projected cost under $1,500 per month."

The patented chemical platform of ROKiT Pharma's key drugs have unprecedented in vitro and in vivo efficacy on 29 major types of cancer (intriguingly, showing activity on p53, AP-1, and NF-kB). Importantly, selective toxicity of ROK-001 on cancer cells rather than non-neoplastic (healthy) cell lines account for its' high therapeutic index, while safety profile evaluations confirm that the compound exerts no genotoxicity nor cardiotoxicity.

Given these results, ROKiT Pharma narrowed its focus for its' first clinical trial to some of the worst cancers that have no current cure - pancreatic and brain (specifically Glioblastoma Multiforme and patients who have had metastases to the brain from other organs).

"Once ROKiT Pharma is able to get FDA approval in one adult cancer type, we plan to divert our focus to childhood cancers," said John Paul DeJoria, ROKiT co-founder and founder of Paul Mitchell Systems and Patron Tequila. "As ROKiT continues to grow globally, we are continuing to add companies that really fulfill our humanitarian goals. Success unshared is failure."

The naturally derived anticancer compounds used to create ROK-001 were discovered through the propolis of Ligurian honey bees only found on Kangaroo Island, which lies off the mainland of South Australia. Propolis is a mixture of beeswax, saps and resins.

In animal studies, ROK-001 demonstrated great efficacy in a multitude of cancer models including pancreatic, melanoma, kidney, bladder, and breast, some in as early as seven days post-oral treatment. Aside from efficacy information, ROK-001 was specifically formulated for oral delivery that not only demonstrated nice biodistribution, but it also revealed that ROK-001 can cross the blood-brain barrier in mice. This discovery led to the decision to target brain cancers.

ROKiT Pharma hopes to fast track this relatively low-toxicity drug for patients with the most deadly cancers. With any proven efficacy in the Phase 1b clinical trial, the FDA may allow an immediate Phase 2 trial to start with an expanded cohort and patient population.

Upon IND approval of ROK-001, the company plans to make the drug available for "Compassionate Use" as is now allowed under the "Right To Try Act" that President Trump signed in 2018.

ROKiT Pharma is presently designing and planning a manufacturing facility (or contract manufacturing facility) in Puerto Rico to act as an established hub for global distribution.

"As the ROKiT brand's awareness continues to grow through our global sports sponsorships - ROKiT Williams Racing Formula 1, ROKiT Venturi Racing Formula E, the Houston Rockets, the Las Vegas Raiders - we are elated to be aggressively entering the pharmaceutical marketplace," said Jonathan Kendrick, co-founder of ROKiT.

The company is optimistic that ROK-001 will move straight into at least one Phase 2 trial and is currently adding philanthropic investors to its capital base.

If there is interest in learning more about ROKiT Pharma or for philanthropic inquiries, please contact info@rokitpharma.com for further information.

About ROKiT Pharma

ROKiT Pharma is a late stage preclinical pharma company focusing its research efforts on cancer. The corporation has an extensive global intellectual property portfolio. Research was developed at and in conjunction with the University of Sydney.

Additional information (*new site under construction Q2/2020): https://www.rokitpharma.com/

Media Contact:
Kristyn Clark
Senior PR Manager
ROKiT Pharma
Tel: (805) 231-1572
kristyn.clark@rokit.com

*LOGO link for media: https://www.Send2Press.com/300dpi/20-0402s2p-rokit-pharma-300dpi.png

ROKiT Pharma, Inc., a public-benefit corporation dedicated to putting patients first, announced today it is rapidly progressing through final preclinical studies and moving forward with preparation for the initiation of a Phase 1b/2 clinical trial of ROK-001, a potentially low toxicity cancer drug derived from natural ingredients.

Related link: https://www.rokitpharma.com/

Boothwyn Pharmacy in Kennett Square Now Manufacturing Hand Sanitizer

KENNETT SQUARE, Pa. /ScoopCloud/ -- Boothwyn Pharmacy, a PCAB-accredited compounding pharmacy located mere minutes from the heart of Kennett Square, Pennsylvania, has dedicated resources to manufacture hand sanitizer.

In response to the rising number of COVID-19 cases, the medical supply shortages created by it, and the increase in reports of homemade hand sanitizers, the FDA has given approval to accredited compounding pharmacies to commence the production of hand sanitizers.

On March 14, 2020, the FDA released new guidance for industry policy regarding the "Temporary Compounding of Certain Alcohol-Based Hand Sanitizers During the Public Health Emergency" to address the need for safe and properly prepared hand sanitizing products that have become commercially unavailable.

Committed to the health and wellbeing of the community, Boothwyn Pharmacy produced its first batch of hand sanitizer on Monday, March 23. This product was compounded in accordance with guidelines set by the FDA and recommendations from the World Health Organization. It contains 75% Isopropyl Alcohol and was made in a state-of-the-art PCAB and NABP-accredited laboratory.

Louis Micolucci, the CEO of Boothwyn Pharmacy, donated the first batch to the Kennett Square and East Marlborough Township police departments and the Longwood Fire Company to ensure the safety of local first responders.

Their hand sanitizer is now available online at https://www.bpimedicalsupply.com/CTGY/COVID19-SUPPLIES.html and can be shipped right to your door.

It is also available at both of their locations: Boothwyn Apothecary in Boothwyn, Pennsylvania, and Boothwyn Pharmacy in Kennett Square, Pennsylvania. Curbside service is available and they will bring hand sanitizer right to your car. Please call ahead to ensure hand sanitizer will be ready for you upon arrival.

About Boothwyn Pharmacy:

Helping the community is not simply an utterance of words for the Boothwyn Pharmacy family, but rather a philosophy that has been engrained in each and every member since their doors first opened in 1933.

Boothwyn Apothecary
2341 Chichester Ave
Boothwyn, PA 19061
610-485-1130

Boothwyn Pharmacy
221 Gale Lane
Kennett Square, PA 19348
1-800-476-7496

Boothwyn Pharmacy, a PCAB-accredited compounding pharmacy located mere minutes from the heart of Kennett Square, Pennsylvania, has dedicated resources to manufacture hand sanitizer.

Related link: https://www.bpimedicalsupply.com/

EPIC Continues Expansion of Employee Benefits Practice with a new Pharmacy Practice Leader

NEW YORK, N.Y. /ScoopCloud/ -- EPIC Insurance Brokers and Consultants, a retail property, casualty insurance brokerage and employee benefits consultant, announced today they are continuing to expand their employee benefits resources with the addition of a new Pharmacy Practice Leader, Bob Eisendrath. We are also pleased to announce that we have promoted Craig Hasday to President, National Employee Benefits Practice leader and Cindy Santangelo to National Voluntary Benefits Practice Leader.

Bob Eisendrath brings a strong background in pharmacy benefit management. He brings experience both in sales and national account management, with CVS Caremark for 20 years where he was most recently Area Vice President for Coalition Business. "The addition of Bob will further strengthen our Pharmacy consulting practice as he leads the team through the rapidly changing legislative and therapeutic landscape as our clients grapple with increasing pharmacy prices, one of the most problematic components of escalating cost," said Craig Hasday, National Employee Benefits Practice Leader.

Craig Hasday has been promoted to President, National Employee Benefits Leader. Said Steve Denton, President, EPIC Holdings, "For the past eighteen months, Craig has led EPIC's National Employee Benefits Operations Board. In that role, Craig has worked closely with the geographic employee benefits leaders and has done an incredible job bringing our national teams together."

During this time, EPIC has seen increased communication and enhancements across the board in service offerings for our clients. Further, EPIC has seen great improvement in revenue growth, profitability, and integration of its vast employee benefits platform. Employee Benefits revenue of over $170 million which represents over 20% of EPIC's retail revenue.

Promoting Cindy Santangelo to the new national role as lead of EPIC's Voluntary Benefits practice highlights EPIC's growing focus on the changing workplace dynamic of offering personalized benefits. Santangelo has been with EPIC for 12 years and spent the past 5 years building and growing the Voluntary Benefits practice within EPIC's national Employee Benefit platform. She brings a wealth of knowledge to her role in employee paid worksite benefits consulting as she fully understands how to create a customized program to meet individualized needs.

"We are fortunate to have someone with her expertise on our team to support our clients and other EPIC consultants," said John Gaffney, VP. National Employee Benefits Operations.

About EPIC Insurance Brokers & Consultants

EPIC is a unique and innovative retail property and casualty and employee benefits insurance brokerage and consulting firm. EPIC has created a values-based, client-focused culture that attracts and retains top talent, fosters employee satisfaction and loyalty and sustains a high level of customer service excellence.

EPIC team members have consistently recognized their company as a "Best Place to Work" in multiple regions and as a "Best Place to Work in the Insurance Industry" nationally.

EPIC now has more than 2,600 team members operating from more than 70 offices across the U.S., providing Property and Casualty, Employee Benefits, Specialty Programs and Private Client solutions to EPIC clients.

With run rate revenues greater than $730 million, EPIC ranks among the top 15 retail insurance brokers in the U.S. Backed and sponsored by Oak Hill Capital Partners, the company continues to expand organically and through strategic acquisitions across the country. For additional information, please visit https://www.epicbrokers.com/.

EPIC Insurance Brokers and Consultants, a retail property, casualty insurance brokerage and employee benefits consultant, announced today they are continuing to expand their employee benefits resources with the addition of a new Pharmacy Practice Leader, Bob Eisendrath.

Related link: https://www.epicbrokers.com/